<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Certolizumab pegol for induction of remission in Crohn's disease - Yamazaki, H - 2019 | Cochrane Library</title> <meta content="Certolizumab pegol for induction of remission in Crohn's disease - Yamazaki, H - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012893.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Certolizumab pegol for induction of remission in Crohn's disease - Yamazaki, H - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012893.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012893.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Certolizumab pegol for induction of remission in Crohn's disease" name="citation_title"/> <meta content="Hajime Yamazaki" name="citation_author"/> <meta content="School of Public Health in the Graduate School of Medicine, Kyoto University" name="citation_author_institution"/> <meta content="yamazaki-myz@umin.ac.jp" name="citation_author_email"/> <meta content="Ryuhei So" name="citation_author"/> <meta content="Kyoto University Graduate School of Medicine/School of Public Health" name="citation_author_institution"/> <meta content="Katsuyoshi Matsuoka" name="citation_author"/> <meta content="Toho University Sakura Hospital" name="citation_author_institution"/> <meta content="Taku Kobayashi" name="citation_author"/> <meta content="Kitasato University Kitasato Institute Hospital" name="citation_author_institution"/> <meta content="Shinichiro Shinzaki" name="citation_author"/> <meta content="Osaka University Graduate School of Medicine" name="citation_author_institution"/> <meta content="Minoru Matsuura" name="citation_author"/> <meta content="Kyoto University Hospital" name="citation_author_institution"/> <meta content="Shinji Okabayashi" name="citation_author"/> <meta content="Kitasato University Kitasato Institute Hospital" name="citation_author_institution"/> <meta content="Yuki Kataoka" name="citation_author"/> <meta content="Hyogo Prefectural Amagasaki General Medical Center" name="citation_author_institution"/> <meta content="Yasushi Tsujimoto" name="citation_author"/> <meta content="School of Public Health in the Graduate School of Medicine, Kyoto University" name="citation_author_institution"/> <meta content="Toshi A Furukawa" name="citation_author"/> <meta content="Kyoto University Graduate School of Medicine/School of Public Health" name="citation_author_institution"/> <meta content="Norio Watanabe" name="citation_author"/> <meta content="Kyoto University Graduate School of Medicine/School of Public Health" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD012893.pub2" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/08/29" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012893.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012893.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012893.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antibodies, Monoclonal, Humanized [*therapeutic use]; Certolizumab Pegol [*therapeutic use]; Crohn Disease [*drug therapy]; Immunologic Factors [therapeutic use]; Induction Chemotherapy; Randomized Controlled Trials as Topic; Remission Induction" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012893.pub2&amp;doi=10.1002/14651858.CD012893.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012893.pub2&amp;doi=10.1002/14651858.CD012893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012893.pub2&amp;doi=10.1002/14651858.CD012893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012893.pub2&amp;doi=10.1002/14651858.CD012893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012893.pub2&amp;doi=10.1002/14651858.CD012893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012893.pub2&amp;doi=10.1002/14651858.CD012893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012893.pub2&amp;doi=10.1002/14651858.CD012893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012893.pub2&amp;doi=10.1002/14651858.CD012893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012893.pub2&amp;doi=10.1002/14651858.CD012893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012893.pub2&amp;doi=10.1002/14651858.CD012893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012893.pub2&amp;doi=10.1002/14651858.CD012893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012893.pub2&amp;doi=10.1002/14651858.CD012893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012893.pub2&amp;doi=10.1002/14651858.CD012893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012893.pub2&amp;doi=10.1002/14651858.CD012893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012893.pub2&amp;doi=10.1002/14651858.CD012893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012893.pub2&amp;doi=10.1002/14651858.CD012893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012893.pub2&amp;doi=10.1002/14651858.CD012893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012893.pub2&amp;doi=10.1002/14651858.CD012893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012893.pub2&amp;doi=10.1002/14651858.CD012893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012893.pub2&amp;doi=10.1002/14651858.CD012893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012893.pub2&amp;doi=10.1002/14651858.CD012893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012893.pub2&amp;doi=10.1002/14651858.CD012893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012893.pub2&amp;doi=10.1002/14651858.CD012893.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="VXKc2U6b";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012893\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012893\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012893\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012893\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ms","fa","fr","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012893.pub2",title:"Certolizumab pegol for induction of remission in Crohn\u0027s disease",firstPublishedDate:"Aug 29, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gut Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=VXKc2U6b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012893.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012893.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012893.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012893.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012893.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012893.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012893.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012893.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012893.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012893.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2129 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012893.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012893.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012893.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012893.pub2/full#CD012893-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012893.pub2/full#CD012893-sec-0084"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012893.pub2/full#CD012893-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012893.pub2/full#CD012893-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012893.pub2/full#CD012893-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012893.pub2/full#CD012893-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012893.pub2/full#CD012893-sec-0060"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012893.pub2/full#CD012893-sec-0078"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012893.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012893.pub2/appendices#CD012893-sec-0089"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012893.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012893.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/table_n/CD012893StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/table_n/CD012893StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012893.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012893.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012893.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012893.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012893.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012893.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Certolizumab pegol for induction of remission in Crohn's disease</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012893.pub2/information#CD012893-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Hajime Yamazaki</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012893.pub2/information#CD012893-cr-0003">Ryuhei So</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012893.pub2/information#CD012893-cr-0004">Katsuyoshi Matsuoka</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012893.pub2/information#CD012893-cr-0005">Taku Kobayashi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012893.pub2/information#CD012893-cr-0006">Shinichiro Shinzaki</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012893.pub2/information#CD012893-cr-0007">Minoru Matsuura</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012893.pub2/information#CD012893-cr-0008">Shinji Okabayashi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012893.pub2/information#CD012893-cr-0009">Yuki Kataoka</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012893.pub2/information#CD012893-cr-0010">Yasushi Tsujimoto</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012893.pub2/information#CD012893-cr-0011">Toshi A Furukawa</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012893.pub2/information#CD012893-cr-0012">Norio Watanabe</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/information/en#CD012893-sec-0092">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 29 August 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012893.pub2">https://doi.org/10.1002/14651858.CD012893.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012893-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012893-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012893-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012893-abs-0002">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012893-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012893-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012893-abs-0001" lang="en"> <section id="CD012893-sec-0001"> <h3 class="title" id="CD012893-sec-0001">Background</h3> <p>Crohn’s disease (CD) is a chronic inflammatory disease of the gastrointestinal tract, and immune response modulation is the main treatment strategy to induce remission in active CD. Certolizumab pegol (CZP) is a tumor necrosis factor‐alfa (TNF‐α) inhibitor which regulates impaired immune response. </p> </section> <section id="CD012893-sec-0002"> <h3 class="title" id="CD012893-sec-0002">Objectives</h3> <p>The primary objectives were to evaluate the efficacy and safety of CZP for the induction of remission in CD. </p> </section> <section id="CD012893-sec-0003"> <h3 class="title" id="CD012893-sec-0003">Search methods</h3> <p>We searched MEDLINE, Embase, CENTRAL, the Cochrane IBD group specialized register, trials registers and other sources from inception to 28 January 2019. Moreover, we contacted the pharmaceutical company that manufactures CZP. </p> </section> <section id="CD012893-sec-0004"> <h3 class="title" id="CD012893-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials comparing CZP with placebo or no treatment in active CD patients. </p> </section> <section id="CD012893-sec-0005"> <h3 class="title" id="CD012893-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methodological procedures. The main outcomes selected for GRADE analysis were clinical remission at week 8 (Crohn’s Disease Activity Index [CDAI] ≤150), clinical response at week 8 (CDAI reduction ≥ 100 or clinical remission), and serious adverse events. The Mantel‐Haenszel random‐effects method was applied for the statistical analyses. For dichotomous outcomes, we calculated the risk ratio (RR) and corresponding 95% confidence interval (95% CI). </p> </section> <section id="CD012893-sec-0006"> <h3 class="title" id="CD012893-sec-0006">Main results</h3> <p>Four studies involving 1485 participants with moderate to severe CD met the inclusion criteria and were used in the meta‐analyses. All studies included active CD patients with CDAI ranging from 220 to 450. Most patients were adults over 18 years of age. One study was identified as high risk of bias due to a non‐identical placebo while the other studies were judged to be at low risk of bias. </p> <p>CZP (100 mg to 400 mg every 2 to 4 weeks) was shown to be superior to placebo for achieving clinical remission at week 8 (RR 1.36, 95% CI 1.11 to 1.66; moderate certainty evidence). The raw numbers of participants achieving clinical remission at week 8 were 26.9% (225/835) and 19.8% (129/650) in the CZP and the placebo groups, respectively. </p> <p>CZP was shown to be superior to placebo for achieving clinical response at week 8 (RR 1.29, 95% CI 1.09 to 1.53; moderate certainty evidence). In raw numbers, clinical response at week 8 was achieved in 40.2% (336/835) and 30.9% (201/650) of participants in the CZP and the placebo groups, respectively. </p> <p>In raw numbers, serious adverse events were observed in 8.7% (73/835) and 6.2% (40/650) of participants in the CZP and the placebo groups, respectively (RR 1.35, 95% CI 0.93 to 1.97; moderate certainty evidence). Serious adverse events included worsening Crohn's disease, infections, and malignancy. </p> </section> <section id="CD012893-sec-0007"> <h3 class="title" id="CD012893-sec-0007">Authors' conclusions</h3> <p>Moderate certainty evidence suggests that CZP is effective for induction of clinical remission and clinical response in participants with active CD patients. It is uncertain whether the risk of serious adverse events differs between CZP and placebo as the 95% CI includes the possibility of a small decrease or doubling of events. Future studies are needed to evaluate the long‐term efficacy and safety of CZP in CD patients. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012893-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012893-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012893-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012893-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012893-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012893-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012893-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012893-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012893-abs-0005" lang="en"> <h3>Certolizumab pegol for the treatment of active Crohn’s disease</h3> <p><b>Review question</b> </p> <p>We reviewed the evidence about the benefits and harms of using certolizumab pegol in people with active Crohn’s disease. </p> <p><b>Background</b> </p> <p>Crohn’s disease is a chronic inflammatory disease that mainly affects the gastrointestinal tract such as the small and large intestine. Common symptoms of Crohn’s disease are chronic diarrhea, abdominal pain, and weight loss. When patients with Crohn’s disease have symptoms, the condition is considered to be 'active'. When in 'remission', patients do not have symptoms. </p> <p>Certolizumab pegol is a biologic medication used to modify the excessive immune response that causes chronic inflammation in Crohn’s disease. Certolizumab pegol is usually injected under the skin every 2 to 4 weeks. </p> <p><b>Study characteristics</b> </p> <p>The literature was searched up to 28 January 2019. Four studies involving 1485 patients compared certolizumab pegol with placebo (a dummy drug). All studies included patients with active Crohn’s disease. Most patients were adults over 18 years of age, except for six patients aged 16 or 17 years old. All studies were funded by the drug manufacturer. </p> <p><b>Key results</b> </p> <p>In a combined analysis of the four studies, patients with active Crohn’s disease who received certolizumab pegol at a dose ranging from 100 mg to 400 mg every 2 to 4 weeks, responded to the treatment and achieved remission at 8 weeks more often than patients taking placebo. No remarkable difference in the rate of serious side effects was observed between certolizumab pegol and placebo. Serious side effects included worsening Crohn's disease, infections, and malignancy (i.e. cancer). </p> <p><b>Quality of the evidence</b> </p> <p>Moderate certainty evidence suggests that certolizumab pegol is beneficial in terms of achieving remission in people with moderate to severe Crohn's disease. Because of a low number of serious side effects, the certainty of evidence about harms of certolizumab pegol was moderate. </p> <p><b>Conclusions</b> </p> <p>Moderate certainty evidence suggests that certolizumab pegol is effective for induction of clinical remission and clinical response in people with active Crohn's disease. It is uncertain whether the risk of serious side effects differs between certolizumab pegol and placebo. Future studies are needed to evaluate the long‐term benefits and harms of certolizumab pegol in people with Crohn's disease. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012893-sec-0084" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012893-sec-0084">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012893-sec-0136">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012893-sec-0084"></div> <h3 class="title" id="CD012893-sec-0085">Implications for practice</h3> <section id="CD012893-sec-0085"> <p>Moderate certainty of evidence suggests that CZP is effective for induction of clinical remission and clinical response in people with moderate to severe CD. It is uncertain whether the risk of serious adverse events differs between CZP and placebo as the 95% CI includes the possibility of a small decrease or doubling of events. </p> </section> <h3 class="title" id="CD012893-sec-0086">Implications for research</h3> <section id="CD012893-sec-0086"> <p>The primary outcome of this review was based on the CDAI, which is a largely subjective measure. This review included CRP improvement as an objective outcome, and we found higher CRP improvement in patients with CZP than those with placebo. We could not analyze endoscopic improvement because there was no relevant study reporting this outcome. Further studies investigating objective outcomes such as endoscopic improvement are needed. </p> <p>This review focuses on induction of remission with CZP in CD as defined in the protocol, and we did not investigate maintenance therapy with CZP for CD. Future systematic reviews are required to evaluate long‐term efficacy (maintenance of remission) and safety of CZP in CD patients. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012893-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012893-sec-0029"></div> <div class="table" id="CD012893-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Certolizumab pegol compared to placebo for induction of remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Certolizumab pegol compared to placebo for induction of remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Patients with active Crohn's disease </p> <p><b>Settings:</b> Outpatient </p> <p><b>Intervention:</b> Certolizumab pegol </p> <p><b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Certolizummab pegol</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical remission</b> </p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>198 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>270 per 1000</b> </p> <p>(220 to 329)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.36</b> </p> <p>(1.11 to 1.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1485<br/> (4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>MODERATE</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certolizumab pegol was shown to be superior to placebo regarding clinical remission at week 8 </p> <p>Clinical remission was defined as a CDAI &lt; 150</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical response</b> </p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>309 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>399 per 1000</b> </p> <p>(337 to 473)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.29</b> </p> <p>(1.09 to 1.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1485</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>MODERATE</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical response was defined as CDAI reduction ≥ 100 from baseline</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>62 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>83 per 1000</b> </p> <p>(57 to 121)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.35</b> </p> <p>(0.93 to 1.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1485</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>MODERATE</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported serious adverse events included worsening Crohn's disease, infections, and malignancy </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; CDAI: Crohn's disease activity index </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to high risk of bias in one study in the pooled analysis </p> <p><sup>2</sup> Downgraded one level due to imprecision (113 events) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012893-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012893-sec-0030">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012893-sec-0100">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD012893-sec-0030"></div> <section id="CD012893-sec-0031"> <h3 class="title" id="CD012893-sec-0031">Description of the condition</h3> <p>Crohn’s disease (CD) is a chronic inflammatory disease that mainly affects the gastrointestinal tract. CD is more common in North America and Europe than in other regions. Nonetheless, both the incidence and prevalence of CD are increasing worldwide. The highest annual incidence of CD was reported to be 5.0, 12.7, and 20.2 per 100,000 person‐years in Asia and the Middle East, Europe and North America, respectively. Moreover, the highest reported prevalence of CD was 67.9, 322, and 318.5 per 100,000 people in Asia and the Middle East, Europe and North America, respectively (<a href="./references#CD012893-bbs2-0031" title="MolodeckyNA , SoonIS , RabiDM , GhaliWA , FerrisM , ChernoffG , et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology2012;142:46‐54. ">Molodecky 2012</a>). </p> <p>Common symptoms of CD include chronic diarrhea, abdominal pain, and weight loss (<a href="./references#CD012893-bbs2-0042" title="TorresJ , MehandruS , ColombelJF , Peyrin‐BirouletL . Crohn's disease. Lancet2016;389:1741‐55. ">Torres 2016</a>), and patients are typically diagnosed with CD in their 20s to 30s (<a href="./references#CD012893-bbs2-0020" title="CosnesJ , Gower‐RousseauC , SeksikP , CortotA . Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology2011;140:1785‐94. ">Cosnes 2011</a>). Up to one third of patients with CD had complications such as stricturing and penetrating disease at diagnosis, and half of these patients needed surgery within 10 years of diagnosis (<a href="./references#CD012893-bbs2-0035" title="Peyrin‐BirouletL , LoftusE VJr , ColombelJF , SandbornWJ . The natural history of adult Crohn's disease in population‐based cohorts. American Journal of Gastroenterology2010;105:289‐97. ">Peyrin‐Biroulet 2010</a>). After the initial surgery, one‐quarter of the patients required a second surgery within five years (<a href="./references#CD012893-bbs2-0023" title="FrolkisAD , LiptonDS , FiestKM , NegronME , DykemanJ , deBruynJ , et al. Cumulative incidence of second intestinal resection in Crohn's disease: a systematic review and meta‐analysis of population‐based studies. American Journal of Gastroenterology2014;109:1739‐48. ">Frolkis 2014</a>). Moreover, the age‐adjusted risk of mortality in patients with CD was 50% higher than that of the general population (<a href="./references#CD012893-bbs2-0019" title="CanavanC , AbramsKR , MayberryJF . Meta‐analysis: mortality in Crohn's disease. Alimentary Pharmacology and Therapeutics2007;25:861‐70. ">Canavan 2007</a>). </p> <p>The etiology of CD is unknown, but abnormal mucosal immune response and impaired barrier function are considered to play an important role in the pathogenesis of CD. Altered intestinal microflora and environmental factors, such as food and smoking, have been postulated to cause immune system dysfunction in genetically susceptible individuals (<a href="./references#CD012893-bbs2-0042" title="TorresJ , MehandruS , ColombelJF , Peyrin‐BirouletL . Crohn's disease. Lancet2016;389:1741‐55. ">Torres 2016</a>). Regulating impaired immune response is the key to CD treatment. </p> </section> <section id="CD012893-sec-0032"> <h3 class="title" id="CD012893-sec-0032">Description of the intervention</h3> <p>The current treatment strategy for inducing remission in active CD is based on immune response modulation. Pharmacologic treatments for induction of remission in CD include corticosteroids, tumor necrosis factor‐alpha (TNF‐α) inhibitors, antibodies to α4β7 integrin, and antibodies to interleukin‐12/23p40. TNF‐α is a pro‐inflammatory cytokine and plays a central role in the inflammatory cascade of CD. Regulating impaired immune response with TNF‐α inhibitors may be key for treatment of CD (<a href="./references#CD012893-bbs2-0017" title="BaumgartDC , SandbornWJ . Crohn's disease. Lancet2012;380:1590‐605. ">Baumgart 2012</a>; <a href="./references#CD012893-bbs2-0033" title="NielsenOH , AinsworthMA . Tumor necrosis factor inhibitors for inflammatory bowel disease. New England Journal of Medicine2013;369:754‐62. ">Nielsen 2013</a>; <a href="./references#CD012893-bbs2-0034" title="OlesenCM , CoskunM , Peyrin‐BirouletL , NielsenOH . Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases. Pharmacology and Therapeutics2016;159:110‐9. ">Olesen 2016</a>; <a href="./references#CD012893-bbs2-0042" title="TorresJ , MehandruS , ColombelJF , Peyrin‐BirouletL . Crohn's disease. Lancet2016;389:1741‐55. ">Torres 2016</a>). </p> <p>Certolizumab pegol (CZP) is a TNF‐α inhibitor. Unlike other TNF‐α inhibitors such as infliximab (IFX) and adalimumab (ADA), CZP is a polyethylene glycolated Fab fragment of a humanized anti‐TNF‐α monoclonal antibody with high affinity for TNF‐α. CZP has no Fc portion and has a different mechanistic profile than other TNF‐ α inhibitors because of its unique structure. The drug lacks the ability to induce regulatory macrophage formation, antibody‐dependent cellular cytotoxicity, complement‐dependent cytotoxicity, and apoptosis via reverse signaling. However, CZP can inhibit inflammatory mediators and increase regulatory T cell activity as effectively as IFX and ADA (<a href="./references#CD012893-bbs2-0024" title="GomollonF , DignassA , AnneseV , TilgH , VanAsscheG , LindsayJO , et al. 3rd European evidence‐based consensus on the diagnosis and management of Crohn's Disease 2016: Part 1: diagnosis and medical management. Journal of Crohn's and Colitis2017;11:3‐25. ">Gomollon 2017</a>; <a href="./references#CD012893-bbs2-0032" title="NesbittA , FossatiG , BerginM , StephensP , StephensS , FoulkesR , et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti‐tumor necrosis factor alpha agents. Inflammatory Bowel Diseases2007;13:1323‐32. ">Nesbitt 2007</a>; <a href="./references#CD012893-bbs2-0034" title="OlesenCM , CoskunM , Peyrin‐BirouletL , NielsenOH . Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases. Pharmacology and Therapeutics2016;159:110‐9. ">Olesen 2016</a>; <a href="./references#CD012893-bbs2-0039" title="ShaoL M , ChenM Y , CaiJ T . Meta‐analysis: the efficacy and safety of certolizumab pegol in Crohn's disease. Alimentary Pharmacology and Therapeutics2009;29:605‐14. ">Shao 2009</a>; <a href="./references#CD012893-bbs2-0042" title="TorresJ , MehandruS , ColombelJF , Peyrin‐BirouletL . Crohn's disease. Lancet2016;389:1741‐55. ">Torres 2016</a>). </p> <p>TNF‐α inhibitors including CZP are recommended for moderately‐to‐severely active CD (<a href="./references#CD012893-bbs2-0024" title="GomollonF , DignassA , AnneseV , TilgH , VanAsscheG , LindsayJO , et al. 3rd European evidence‐based consensus on the diagnosis and management of Crohn's Disease 2016: Part 1: diagnosis and medical management. Journal of Crohn's and Colitis2017;11:3‐25. ">Gomollon 2017</a>; <a href="./references#CD012893-bbs2-0040" title="TalleyN J , AbreuM T , AchkarJ P , BernsteinC N , DubinskyM C , HanauerS B , et al. An evidence‐based systematic review on medical therapies for inflammatory bowel disease. American Journal of Gastroenterology2011;106(Suppl 1):S2‐25; quiz S26. ">Talley 2011</a>; <a href="./references#CD012893-bbs2-0041" title="TerdimanJP , GrussCB , HeidelbaughJJ , SultanS , Falck‐YtterYT , Practice AGA Institute Clinical, et al. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti‐TNF‐alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology2013;145:1459‐63. ">Terdiman 2013</a>; <a href="./references#CD012893-bbs2-0042" title="TorresJ , MehandruS , ColombelJF , Peyrin‐BirouletL . Crohn's disease. Lancet2016;389:1741‐55. ">Torres 2016</a>). CZP is approved for the treatment of CD in the United States and Switzerland (<a href="./references#CD012893-bbs2-0034" title="OlesenCM , CoskunM , Peyrin‐BirouletL , NielsenOH . Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases. Pharmacology and Therapeutics2016;159:110‐9. ">Olesen 2016</a>; <a href="./references#CD012893-bbs2-0042" title="TorresJ , MehandruS , ColombelJF , Peyrin‐BirouletL . Crohn's disease. Lancet2016;389:1741‐55. ">Torres 2016</a>). CZP is a subcutaneously delivered drug and can be self‐administered. Potential serious adverse events of CZP are anaphylactic reaction, lymphoproliferative disorder, tuberculosis reactivation, and opportunistic infection (<a href="./references#CD012893-bbs2-0024" title="GomollonF , DignassA , AnneseV , TilgH , VanAsscheG , LindsayJO , et al. 3rd European evidence‐based consensus on the diagnosis and management of Crohn's Disease 2016: Part 1: diagnosis and medical management. Journal of Crohn's and Colitis2017;11:3‐25. ">Gomollon 2017</a>). </p> </section> <section id="CD012893-sec-0033"> <h3 class="title" id="CD012893-sec-0033">How the intervention might work</h3> <p>CZP inhibits TNF‐α receptor activation by neutralizing both the transmembrane form of TNF‐α (tmTNF) and soluble form of TNF‐α (sTNF). Currently, tmTNF signaling is considered to have a central role in the pathogenesis of CD, and CZP can bind to both sTNF and tmTNF. CZP regulates impaired immune response through the following possible mechanisms of action: increased regulatory T cell frequency and activity, inflammatory mediator suppression in immune cells, decreased inflammatory mediators by reverse signaling in tmTNF‐expressing cells, and nonapoptotic cytotoxicity and apoptosis by blocking tmTNF‐mediated TNF‐α receptor activation (<a href="./references#CD012893-bbs2-0034" title="OlesenCM , CoskunM , Peyrin‐BirouletL , NielsenOH . Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases. Pharmacology and Therapeutics2016;159:110‐9. ">Olesen 2016</a>). </p> </section> <section id="CD012893-sec-0034"> <h3 class="title" id="CD012893-sec-0034">Why it is important to do this review</h3> <p>Recent meta‐analyses have shown inconsistent results, which may be due to differences in methodology and in the selected time points for the assessment of clinical remission (<a href="./references#CD012893-bbs2-0022" title="FordAC , SandbornWJ , KhanKJ , HanauerSB , TalleyNJ , MoayyediP . Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta‐analysis. American Journal of Gastroenterology2011;106:644‐59. ">Ford 2011</a>; <a href="./references#CD012893-bbs2-0029" title="KawalecP , MikrutA , WisniewskaN , PilcA . Tumor necrosis factor‐alpha antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta‐analysis. Archives of Medical Science2013;9:765‐79. ">Kawalec 2013</a>). In one review (<a href="./references#CD012893-bbs2-0022" title="FordAC , SandbornWJ , KhanKJ , HanauerSB , TalleyNJ , MoayyediP . Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta‐analysis. American Journal of Gastroenterology2011;106:644‐59. ">Ford 2011</a>), there was no difference between CZP and placebo in the proportion of participants who failed to achieve remission at weeks 6 to 12 (risk ratio [RR] 0.95, 95% confidence interval [CI] 0.90 to 1.01). Another review (<a href="./references#CD012893-bbs2-0029" title="KawalecP , MikrutA , WisniewskaN , PilcA . Tumor necrosis factor‐alpha antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta‐analysis. Archives of Medical Science2013;9:765‐79. ">Kawalec 2013</a>) found a benefit for induction of remission for CZP over placebo at week four (RR 1.63, 95% CI 1.32 to 2.13). We are also aware of at least one unpublished trial (NCT00291668). The current review will summarize and properly integrate all of the available evidence, including unpublished randomized controlled trials (RCTs), to provide the best available evidence to assess the efficacy and safety of CZP for induction of remission in CD. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012893-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012893-sec-0035">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012893-sec-0105">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012893-sec-0035"></div> <p>The primary objectives were to evaluate the efficacy and safety of CZP for induction of remission in CD. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012893-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012893-sec-0036">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012893-sec-0106">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012893-sec-0036"></div> <section id="CD012893-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012893-sec-0038"> <h4 class="title">Types of studies</h4> <p>This review included RCTs irrespective of publication status. No language status restrictions were applied. </p> </section> <section id="CD012893-sec-0039"> <h4 class="title">Types of participants</h4> <p>Participants included patients (≥ 16 years old) with active CD that was diagnosed by standard clinical, endoscopic, radiographic, and histopathological assessment. Active CD was defined as having a Crohn’s Disease Activity Index (CDAI) score greater than 150 or a Harvey‐Bradshaw Index (HBI) score greater than 4 (<a href="./references#CD012893-bbs2-0018" title="BestWR , BecktelJM , SingletonJW , KernFJr . Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology1976;70:439‐44. ">Best 1976</a>; <a href="./references#CD012893-bbs2-0026" title="HarveyRF , BradshawJM . A simple index of Crohn's‐disease activity. Lancet1980;1:514. ">Harvey 1980</a>). </p> </section> <section id="CD012893-sec-0040"> <h4 class="title">Types of interventions</h4> <p>Subcutaneous administration of any dose of CZP every two to four weeks compared to placebo or no treatment. Active comparators such as conventional treatment (including 5‐aminosalicylic acid, immunomodulators, or corticosteroids) were not included in this review. </p> </section> <section id="CD012893-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD012893-sec-0042"> <h5 class="title">Primary outcomes</h5> <p>The primary outcome was the proportion of CD patients achieving remission at week eight after CZP administration. We selected week eight because this week is the recommended time for switching to maintenance dosing according to the approved dosing regimen (<a href="./references#CD012893-bbs2-0037" title="SchreiberS . Certolizumab pegol for the treatment of Crohn's disease. Therapeutic Advances in Gastroenterology2011;4(6):375‐89. ">Schreiber 2011</a>). If the outcome was not assessed at week 8, we selected the nearest week between weeks 4 and 12 as the outcome assessment point. If only dates from two time points equally distant from week 8, such as weeks 6 and 10, were available despite inquiring with the original investigators, the earlier point (week 6) was planned to be selected. Remission was defined as CDAI ≤ 150 or HBI ≤ 4. If both CDAI and HBI were reported in the primary studies, the CDAI was planned to be used for outcome assessment. The proportion of participants in remission was calculated in accordance with the intention‐to‐treat (ITT) principle; the denominator was the number of the randomized patients in each arm. Participants with missing data for the primary outcome were assumed to be treatment failures. </p> </section> <section id="CD012893-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p>Secondary outcomes included the proportion of participants with:</p> <p> <ul id="CD012893-list-0001"> <li> <p>clinical response at week eight;</p> </li> <li> <p>C‐reactive protein (CRP) improvement at week eight;</p> </li> <li> <p>health‐related quality of life at week eight;</p> </li> <li> <p>endoscopic improvement at week twelve;</p> </li> <li> <p>fistula closure at week eight;</p> </li> <li> <p>adverse events;</p> </li> <li> <p>serious adverse events; and</p> </li> <li> <p>withdrawals due to adverse events.</p> </li> </ul> </p> <p>Clinical response was defined as a CDAI reduction from baseline of greater than or equal to 100 or remission (CDAI ≤ 150) or an HBI reduction from baseline of greater than or equal to 3 or remission (HBI ≤ 4) (<a href="./references#CD012893-bbs2-0043" title="VermeireS , SchreiberS , SandbornW J , DuboisC , RutgeertsP . Correlation between the Crohn's disease activity and Harvey‐Bradshaw indices in assessing Crohn's disease severity. Clinical Gastroenterology and Hepatology2010;8:357‐63. ">Vermeire 2010</a>). For outcomes that were not available for week 8, we selected the nearest week between weeks 4 and 12. If only two assessment points equally distant from week 8 were available, such as weeks 6 and 10, despite inquiring with the original investigators, the earlier point (week 6) was planned to be selected. We followed this procedure for all outcomes that we intended to assess at eight weeks. The assessment for C‐reactive protein (CRP) improvement at week eight was based on log scales of geometric mean CRP ratios between baseline and week eight. The assessment for health‐related quality of life at week eight was based on the mean change in quality of life scores from baseline as measured by a validated instrument including the Inflammatory Bowel Disease Questionnaire (IBDQ) (<a href="./references#CD012893-bbs2-0025" title="GuyattG , MitchellA , IrvineE J , SingerJ , WilliamsN , GoodacreR , et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology1989;96:804‐10. ">Guyatt 1989</a>) or the Medical Outcomes Study Short‐Form 36 (SF‐36) questionnaire (<a href="./references#CD012893-bbs2-0044" title="WareJEJr , SherbourneCD . The MOS 36‐item short‐form health survey (SF‐36). I. Conceptual framework and item selection. Medical Care1992;30(6):473‐83. ">Ware 1992</a>). If endoscopic outcomes were not reported for week 12, we planned to select the nearest week between weeks 8 and 26. We also planned to assess endoscopic improvement by calculating the mean change from baseline in the Crohn’s Disease Endoscopic Index of Severity (CDEIS), the Simplified Endoscopic Activity Score for Crohn’s Disease (SES‐CD), or the Rutgeerts score (<a href="./references#CD012893-bbs2-0021" title="DapernoM , D'HaensG , VanAsscheG , BaertF , BuloisP , MaunouryV , et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES‐CD. Gastrointestinal Endoscopy2004;60:505‐12. ">Daperno 2004</a>; <a href="./references#CD012893-bbs2-0030" title="MaryJY , ModiglianiR . Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut1989;30:983‐9. ">Mary 1989</a>; <a href="./references#CD012893-bbs2-0036" title="RutgeertsP , GeboesK , VantrappenG , BeylsJ , KerremansR , HieleM . Predictability of the postoperative course of Crohn's disease. Gastroenterology1990;99:956‐63. ">Rutgeerts 1990</a>). If only two assessment points equally distant from week 12 were available, such as weeks 10 and 14, despite inquiring with the original investigators, the earlier point (week 10) was planned to be selected. Adverse and serious adverse events were based on what was reported in the primary studies. </p> </section> </section> </section> <section id="CD012893-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012893-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We conducted a comprehensive literature search without language restrictions. We searched the following databases to identify relevant RCTs: </p> <p> <ul id="CD012893-list-0002"> <li> <p>MEDLINE (inception to date);</p> </li> </ul> <ul id="CD012893-list-0003"> <li> <p>Embase (inception to date);</p> </li> </ul> <ul id="CD012893-list-0004"> <li> <p>CENTRAL;</p> </li> </ul> <ul id="CD012893-list-0005"> <li> <p>The Cochrane IBD Group Specialized Register (inception to date);</p> </li> </ul> <ul id="CD012893-list-0006"> <li> <p>http://ClinicalTrials.gov (trial registry);</p> </li> </ul> <ul id="CD012893-list-0007"> <li> <p>https://www.clinicaltrialsregister.eu/ (EU Clinical Trials Register);</p> </li> </ul> <ul id="CD012893-list-0008"> <li> <p>http://apps.who.int/trialsearch/ (International Clinical Trials Registry Platform); and </p> </li> </ul> <ul id="CD012893-list-0009"> <li> <p>http://www.ucb.com/our‐science/Our‐clinical‐studies/cimzia‐certolizumab‐pegol (web site of a pharmaceutical company producing CZP). </p> </li> </ul> </p> <p>The search strategies are reported in <a href="./appendices#CD012893-sec-0090">Appendix 1</a>. </p> </section> <section id="CD012893-sec-0046"> <h4 class="title">Searching other resources</h4> <p>To identify additional studies, we searched the following resources manually or through personal contacts: </p> <p> <ul id="CD012893-list-0010"> <li> <p>Abstracts of Digestive Disease Week, United European Gastroenterology Week, European Crohn’s and Colitis Organization Congress, and Advances in Inflammatory Bowel Diseases (2000 to date); </p> </li> </ul> <ul id="CD012893-list-0011"> <li> <p>References from published articles; and</p> </li> </ul> <ul id="CD012893-list-0012"> <li> <p>Pharmaceutical companies and experts involved in the development of CZP.</p> </li> </ul> </p> </section> </section> <section id="CD012893-sec-0047"> <h3 class="title" id="CD012893-sec-0047">Data collection and analysis</h3> <section id="CD012893-sec-0048"> <h4 class="title">Selection of studies</h4> <p>Two authors (HY and RS) independently screened titles and abstracts, and selected potential eligible studies based on the above criteria. In addition, these authors independently read the full‐text articles of the potential eligible studies and decided which studies should be included in the review. In cases of insufficient information, we contacted the authors of the primary studies to evaluate eligibility for inclusion. In the event of a disagreement regarding study selection, HY and RS discussed the matter together to reach a consensus. NW acted as the arbitrator when consensus was not reached. </p> </section> <section id="CD012893-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>Two authors (HY and RS) independently extracted data using data extraction forms to record data from the selected studies. Any disagreements were resolved through discussion. NW was the arbitrator when consensus was not reached. </p> <p>We extracted the following data:</p> <p> <ul id="CD012893-list-0013"> <li> <p>Characteristics of the primary studies: publication year, country, study recruitment period, study completion date, study type, and risk of bias items; </p> </li> </ul> <ul id="CD012893-list-0014"> <li> <p>Participant characteristics: country, total number of participants, number of participants randomized, number of participants analyzed in each group, age, sex, ethnicity, body mass index, disease duration, disease site, smoking status, CDAI score, HBI score, CDEIS, SES‐CD, Rutgeerts score, IBDQ score, SF‐36 score, CRP, fistula, concurrent CD treatment, previous CD treatment, inclusion criteria, and exclusion criteria; </p> </li> </ul> <ul id="CD012893-list-0015"> <li> <p>Intervention characteristics: dose, delivery route, and administration schedule of CZP; </p> </li> </ul> <ul id="CD012893-list-0016"> <li> <p>Comparator characteristics: placebo or no treatment control;</p> </li> </ul> <ul id="CD012893-list-0017"> <li> <p>Outcomes: proportion of participants who achieved clinical remission at week 8, proportion of participants with clinical response at week 8, CDAI score at week 8, HBI score at week 8, CDEIS at week 12, SES‐CD at week 12, Rutgeerts score at week 12, IBDQ score at week 8, SF‐36 score at week 8, CRP at week 8, fistula closure at week 8, any adverse events, adverse events leading to withdrawal, serious adverse events, time of outcome assessment in primary studies, length of follow‐up, number of participants lost to follow‐up, reasons for loss to follow‐up, number of participants who did not complete treatment, reasons for incomplete treatment, and criteria for evaluating outcomes in primary studies. </p> </li> </ul> </p> <p>We contacted the authors of the primary studies and the pharmaceutical company that manufactures CZP if information in the published reports was insufficient. </p> </section> <section id="CD012893-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two authors (HY and RS) independently assessed the quality of included studies using the Cochrane risk of bias tool (<a href="./references#CD012893-bbs2-0028" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assesing risk of bias in included studies. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Any disagreements were resolved by consensus with a third author (NW). Primary studies were rated as high, low, or unclear risk of bias. We assessed the following risk of bias items: random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), and other potential sources of bias. </p> <p>We rated random sequence generation as low risk of bias if the method for random sequence generation was described as a random number table, computer‐generated, coin tossing, shuffling cards or envelopes, throwing dice, drawing of lots or minimization. We rated random sequence generation as high risk of bias if the method of generation was not random. Examples included a systematic approach, such as date or record number, or a non‐systematic approach, such as preference and availability. We rated random sequence generation as unclear risk of bias if insufficient information was reported to allow for a judgement. </p> <p>We rated allocation concealment as low risk of bias if allocation could not be foreseen by participants and investigators. Adequate methods of allocation concealment included centralized allocation such as telephone, web‐based, or pharmacy‐controlled randomization, sequentially numbered drug containers of the same appearance, or sequentially numbered, opaque, sealed envelopes. We rated allocation concealment as high risk of bias if the allocation sequence was likely to be foreseen. Examples included an open random allocation schedule or envelopes without safeguards. We rated allocation concealment as unclear risk of bias if insufficient information was reported to allow for a judgement. </p> <p>We rated blinding of participants and personnel and blinding of outcome assessors as low risk of bias if proper methods were employed to prevent knowledge of treatment assignment (e.g. double‐blinding with an identical placebo) or if no blinding or incomplete blinding of participants or personnel was unlikely to affect assessment of the outcome (e.g. a serious adverse event resulting in death). We rated blinding of participants and personnel and blinding of outcomes assessors as high risk of bias if blinding was likely to be broken and this could affect outcome assessment, or if there was no blinding or incomplete blinding of participants or personnel or outcome assessors which could affect outcome assessment. We rated blinding of participants and personnel and blinding of outcome assessors as unclear risk of bias if insufficient information was reported to allow for a judgement. </p> <p>We rated incomplete outcome data as low risk of bias when there were no missing outcome data; when missing outcome data were unlikely to be related to the true outcome; when the number of dropouts and reasons for withdrawal were balanced between treatment groups; when compared to the observed event, the proportion of missing outcomes did not have a clinically relevant impact on the effect estimate for dichotomous outcomes; when the expected effect size among missing outcomes did not have clinically relevant impact on the observed effect size for continuous outcome data; or when missing data were imputed using proper methods. We rated incomplete outcome data as high risk of bias when missing outcome data were likely to be related to the true outcome; when numbers or reasons for missing data were imbalanced across treatment groups; when compared with the observed event, the proportion of missing outcomes had a clinically relevant impact on the effect estimate for dichotomous outcomes; when the expected effect size among missing outcomes had a clinically relevant impact on the observed effect size for continuous outcomes; when an 'as‐treated analysis' was substantially performed; and when missing data were imputed using improper methods (e.g. simple imputation). We rated incomplete outcome data as unclear risk of bias when insufficient information was reported to allow for a judgement. </p> <p>We rated selective reporting as low risk of bias when the protocols of primary studies were available, and all of the primary and secondary study outcomes related to this systematic review, were reported in a pre‐defined way; and when the study protocols were unavailable, but all of the expected outcomes, related to this systematic review, were reported. We rated selective outcome reporting as high risk of bias when pre‐defined primary outcomes related to this systematic review were not thoroughly reported; when those primary outcomes were measured or analyzed in a way that was different to the protocol; when reported primary outcomes related to this systematic review were different from those in the protocol; when the outcomes were not completely reported; and when key outcomes were not included in the primary studies. We rated selective outcome reporting as unclear risk of bias when insufficient information was reported to allow for a judgement. </p> <p>We rated studies as low risk of bias for other sources of bias when the study appeared to be free of other potential sources of bias. We rated studies as high risk of bias for other sources of bias when other sources of bias could have an impact on the study outcomes. For example, fraudulent studies or baseline imbalances in demographic factors. We rated studies as unclear risk of bias for other sources of bias when the study reported insufficient details to allow for a judgement. We contacted study authors for additional information to clarify the risk of bias when the study reports did not provide enough detail to allow for a clear judgement. </p> </section> <section id="CD012893-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous outcomes, we calculated the risk ratio (RR) and corresponding 95% confidence interval (CI). ITT analyses were conducted for dichotomous outcomes, whereby all dropouts were assumed to be treatment failures. We calculated the mean difference (MD) and 95% CI for continuous outcomes. When different scales were used to measure the same construct, we planned to calculate the standardized mean difference (SMD) and 95% CI. </p> </section> <section id="CD012893-sec-0052"> <h4 class="title">Unit of analysis issues</h4> <p>We collected outcomes per randomized participant. For cross‐over trials, we planned to use data from the first phase before the cross‐over. Cluster RCTs were not included in this review. If events occurred more than once (e.g. adverse events), we reported on the proportion of participants who experienced at least one event. To avoid double counting of the comparator for multi‐arm studies (multiple dose groups), the number of patients in the comparator group (i.e. placebo or no treatment control) were divided across the number of eligible CZP arms. To deal with multiple observations for the same outcome in primary studies, we precisely defined the outcome assessment points for both primary and secondary outcomes. </p> </section> <section id="CD012893-sec-0053"> <h4 class="title">Dealing with missing data</h4> <p>We contacted authors of the primary studies and the pharmaceutical company that manufactures CZP to obtain missing data and the reason for missing data. If it was not possible to obtain the missing data, we reported as such in the results. For dichotomous outcomes, all missing data were treated as treatment failures in the ITT analyses. We conducted sensitivity analyses using available case data to assess the impact on the effect estimate. For continuous outcomes, we did not use any imputation methods, and used the available data only. </p> </section> <section id="CD012893-sec-0054"> <h4 class="title">Assessment of heterogeneity</h4> <p>Clinical heterogeneity was first assessed with regard to patient characteristics, such as previous treatment and concurrent medication. If the studies were clinically homogenous, statistical heterogeneity was evaluated using the Chi² test and I² statistic. A P value of less than or equal to 0.10 for the Chi² test was considered to show statistically significant heterogeneity. The I² statistic estimates the degree of statistical heterogeneity. We considered an I² value of 25% to indicate low heterogeneity, a value of 50% to indicate moderate heterogeneity and a value of 75% to indicate high heterogeneity. If statistical heterogeneity existed, we planned to perform a visual inspection of the forest plots to identify potential outliers causing the heterogeneity. Moreover, sensitivity and subgroup analyses were planned to explore potential sources of heterogeneity when significant or moderate‐high heterogeneity was identified (<a href="./references#CD012893-bbs2-0027" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>; <a href="./references#CD012893-bbs2-0028" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assesing risk of bias in included studies. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD012893-sec-0055"> <h4 class="title">Assessment of reporting biases</h4> <p>We searched for both registered and published trials, and reported on the proportion of registered trials that were unpublished. We contacted the investigators of the unpublished trials and the pharmaceutical company that manufactures CZP to provide data related to outcomes in this systematic review. If we could not obtain these data, we reported as such in this review. When there were 10 or more eligible trials in a pooled analysis, we planned to generate funnel plots to evaluate potential publication bias. Moreover, when we found unclear or high risk of bias for selective reporting, we contacted the study authors and the pharmaceutical company that manufactures CZP to provide unpublished outcome data. If we could not obtain these data, we reported so in the results. </p> </section> <section id="CD012893-sec-0056"> <h4 class="title">Data synthesis</h4> <p>When included studies were sufficiently similar from the clinical and statistical viewpoints, we conducted meta‐analyses. Data were analyzed using Review Manager 5.3, and a random‐effects model was used for the meta‐analyses. A P value of less than 0.05 was considered to be statistically significant. </p> <p>On the basis of the characteristics of participants, interventions, and outcomes in primary studies, clinical similarity was determined by consensus between HY and KM. In cases of disagreement between HY and KM, the authors consulted with TK to resolve the disagreement. In cases of high heterogeneity (I² statistic ≥ 75%), meta‐analyses were not planned, and each study was planned to be described in detail. </p> </section> <section id="CD012893-sec-0057"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If sufficient data were available, the following subgroup analyses were planned for the primary outcomes: </p> <p> <ul id="CD012893-list-0018"> <li> <p>Disease severity at baseline (150 &lt; CDAI &lt; 220, 220 ≤ CDAI ≤ 450, CDAI &gt; 450);</p> </li> </ul> <ul id="CD012893-list-0019"> <li> <p>CRP levels at baseline (CRP levels &lt; 10 mg/L, CRP levels ≥ 10 mg/L);</p> </li> </ul> <ul id="CD012893-list-0020"> <li> <p>Doses of CZP (CZP &lt; 200 mg, 200 mg ≤ CZP &lt; 400 mg, 400 mg ≤ CZP &lt; 600 mg, and CZP ≥ 600 mg); and </p> </li> </ul> <ul id="CD012893-list-0021"> <li> <p>Previous treatment with other TNF‐α inhibitors (yes, no).</p> </li> </ul> </p> </section> <section id="CD012893-sec-0058"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform the following sensitivity analyses for primary outcomes:</p> <p> <ul id="CD012893-list-0022"> <li> <p>Excluding studies judged to be at high risk of bias for any domain of the risk of bias tool; </p> </li> </ul> <ul id="CD012893-list-0023"> <li> <p>Excluding studies judged to be at high or unclear risk of bias for any domain of the risk of bias tool; </p> </li> </ul> <ul id="CD012893-list-0024"> <li> <p>Using available case data instead of ITT analysis for missing dichotomous outcome data; </p> </li> </ul> <ul id="CD012893-list-0025"> <li> <p>Selecting later outcome assessment points if only dates from two time points equally distant from the defined outcome assessment points were available despite inquiring with the original investigators. For example, if only dates from two time points equally distant from week 8, such as weeks 6 and 10, were available, week 10 was planned to be selected in the sensitivity analysis. </p> </li> </ul> <ul id="CD012893-list-0026"> <li> <p>Limiting the included studies that administered CZP strictly in accordance with the approved regimen which is subcutaneous administration of 400 mg CZP at weeks 0, 2, and 4, and then every 4 weeks. </p> </li> </ul> </p> <section id="CD012893-sec-0059"> <h5 class="title">Summary of findings tables</h5> <p>We produced 'Summary of findings' tables using the GRADEpro Guideline Development Tool for the following outcomes: clinical remission, clinical response, and serious adverse events. </p> <p>The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to evaluate the certainty of the evidence supporting each outcome. Evidence from RCTs starts as high quality, but can be downgraded due to risk of bias, inconsistency across studies, indirectness of evidence, imprecision of effect estimate, and publication bias (<a href="./references#CD012893-bbs2-0038" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP . Chapter 12: Interpreting results and drawing conclusions. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011</a>). If serious limitations were present, we downgraded the evidence level by one. Moreover, very serious limitations can lead to downgrading of the evidence by two levels (<a href="./references#CD012893-bbs2-0038" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP . Chapter 12: Interpreting results and drawing conclusions. In: HigginsJPT , GreenS editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org, 2011. Available from www.cochrane‐handbook.org. ">Schünemann 2011</a>). HY and RS independently assessed the certainty of evidence for each outcome and the overall quality of the evidence was rated as: </p> <p> <ul id="CD012893-list-0027"> <li> <p>High: We are very confident that the true effect lies close to that of the effect estimate; </p> </li> </ul> <ul id="CD012893-list-0028"> <li> <p>Moderate: We are moderately confident in the effect estimate: the true effect is likely to be close to the effect estimate, but it could be substantially different; </p> </li> </ul> <ul id="CD012893-list-0029"> <li> <p>Low: Our confidence in the effect estimate is limited: the true effect may be substantially different from the effect estimate; or </p> </li> </ul> <ul id="CD012893-list-0030"> <li> <p>Very low: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the effect estimate. </p> </li> </ul> </p> <p>In cases of disagreement between HY and RS, we consulted with NW.</p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012893-sec-0060" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012893-sec-0060"></div> <section id="CD012893-sec-0061"> <h3 class="title">Description of studies</h3> <section id="CD012893-sec-0062"> <h4 class="title">Results of the search</h4> <p>The literature search was conducted on 28 January 2019 and 623 studies were identified. After removing duplicates, 423 reports remained for the title and abstract screening. Two authors independently screened the 423 reports, and 26 full‐text reports were assessed for further eligibility. Twelve reports of four studies (1485 participants) were finally included in this systematic review and a total of 14 reports of 12 studies were excluded (see <a href="#CD012893-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD012893-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012893-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD012893-sec-0063"> <h4 class="title">Included studies</h4> <p>The four studies included in this systematic review are summarized in the <a href="./references#CD012893-sec-0098" title="">Characteristics of included studies</a> table. All four studies were randomized, double‐blind, placebo‐controlled multicenter trials sponsored by UCB Inc, the manufacturer of CZP. All the study participants were active CD patients whose CDAI was between 220 and 450. Follow‐up periods ranged between 6 weeks and 28 weeks. </p> <p><a href="./references#CD012893-bbs2-0004" title="RutgeertsP , SchreiberS , FeaganB , KeiningerDL , O'NeilL , FedorakRN . Certolizumab pegol, a monthly subcutaneously administered Fc‐free anti‐TNFalpha, improves health‐related quality of life in patients with moderate to severe Crohn's disease. International Journal of Colorectal Disease2008;23(3):289‐96. SchreiberS , RutgeertsP , FedorakR , Khaliq‐KareemiM , KammMA , PatelJ , et al. CDP870, a humanized anti‐TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease (CD). Gastroenterology. 2003; Vol. 124:A61. SchreiberS , RutgeertsP , FedorakRN , Khaliq‐KareemiM , KammMA , BoivinM , et al. A randomized, placebo‐controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology2005;129(3):807‐18. ">Schreiber 2005</a> compared three different doses (100 mg, 200 mg, or 400 mg) of CZP with placebo in adult patients (18 to 75 years, N = 292). CZP was administered subcutaneously at weeks zero, four and eight. The primary outcome was clinical response (&gt; 100 points CDAI decrease) or remission (CDAI ≤ 150) at week 12. </p> <p><a href="./references#CD012893-bbs2-0002" title="NCT00152490 . A study to test the effect of CDP870 in the treatment of Crohn's disease over 26 weeks, comparing CDP870 to a dummy drug (placebo). https://clinicaltrials.gov/ct2/show/NCT00152490. SandbornWJ , FeaganBG , HoniballPJ , RutgeertsP , MasonD , BloomfieldR , et al. Certolizumab pegol for the treatment of Crohn's disease. New England Journal of Medicine2007;357(3):228‐38. SandbornWJ , FeaganBG , StoinovS , HoniballPJ , RutgeertsP , McColmJA . Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26‐week, placebo controlled phase III study (PRECiSE 1). Gastroenterology. 2006; Vol. 130:A107‐8. ">Sandborn 2007</a> compared 400 mg of CZP with placebo in adult patients (≥ 18 years, N = 660). CZP was administered subcutaneously at weeks zero, two and four, and then every four weeks. The primary outcome was clinical response (&gt; 100 points CDAI decrease) at week 6 and at both weeks 6 and 26 in patients with a baseline serum CRP ≥ 10 mg/L. Clinical remission (CDAI ≤ 150) at week 6 was a secondary outcome. </p> <p><a href="./references#CD012893-bbs2-0001" title="NCT00291668 . Clinical study of CDP870/Certolizumab Pegol in patients with active Crohn's disease. https://clinicaltrials.gov/ct2/show/study/NCT00291668. OgataH , ItoH , MotoyaS , TakazoeM , SuzukiY , MatsumotoT , et al. Certolizumab pegol is effective at inducing and maintaining response and remission in Japanese patients with Crohn’s disease: Results from induction and maintenance studies. Gut. 2009; Vol. 58:A170. ">Ogata 2009</a> compared two different doses (200 mg or 400 mg) of CZP with placebo in patients with CRP ≥ 10 mg/L (16 to 65 years, N = 94). Only two participants were aged 16 or 17 years old in each group. CZP was administered subcutaneously at weeks zero, two and four. The primary outcome was clinical response (&gt; 100 points CDAI decrease) or remission (CDAI ≤ 150) at week 6. </p> <p><a href="./references#CD012893-bbs2-0003" title="EUCTR‐001913‐41 . A phase IIIb, multinational, randomized, double‐blind, placebo‐controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti‐TNF‐alpha monoclonal antibody, administered subcutaneously at weeks 0, 2 and 4 in subjects with moderately to severely active Crohn’s disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=2007‐001913‐41. NCT00552058 . Study to evaluate efficacy and safety of certolizumab pegol for induction of remission in patients with Crohn's disease. https://ClinicalTrials.gov/show/NCT00552058. SandbornW , SchreiberS , FeaganB , RutgeertsP , YounesZ , BloomfieldR , et al. Induction therapy with certolizumab pegol in patients with moderate to severe Crohn's disease: a placebo‐controlled trial. American Journal of Gastroenterology. 2010; Vol. 105:S419. SandbornWJ , SchreiberS , FeaganBG , RutgeertsP , YounesZH , BloomfieldR , et al. Certolizumab pegol for active Crohn's disease: a placebo‐controlled, randomized trial. Clinical Gastroenterology &amp; Hepatology2011;9(8):670‐8. ">Sandborn 2011</a> compared 400 mg of CZP with placebo in adult patients without previous treatment with TNF‐α inhibitors (18 to 75 years, N = 439). CZP was administered subcutaneously at weeks zero, two and four. The primary outcome was clinical remission (CDAI ≤ 150) at week 6. </p> <p>We contacted UCB Inc and obtained the following information: a protocol of <a href="./references#CD012893-bbs2-0004" title="RutgeertsP , SchreiberS , FeaganB , KeiningerDL , O'NeilL , FedorakRN . Certolizumab pegol, a monthly subcutaneously administered Fc‐free anti‐TNFalpha, improves health‐related quality of life in patients with moderate to severe Crohn's disease. International Journal of Colorectal Disease2008;23(3):289‐96. SchreiberS , RutgeertsP , FedorakR , Khaliq‐KareemiM , KammMA , PatelJ , et al. CDP870, a humanized anti‐TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease (CD). Gastroenterology. 2003; Vol. 124:A61. SchreiberS , RutgeertsP , FedorakRN , Khaliq‐KareemiM , KammMA , BoivinM , et al. A randomized, placebo‐controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology2005;129(3):807‐18. ">Schreiber 2005</a>; a presentation poster from the United European Gastroenterology 2009, detailed information from <a href="./references#CD012893-bbs2-0001" title="NCT00291668 . Clinical study of CDP870/Certolizumab Pegol in patients with active Crohn's disease. https://clinicaltrials.gov/ct2/show/study/NCT00291668. OgataH , ItoH , MotoyaS , TakazoeM , SuzukiY , MatsumotoT , et al. Certolizumab pegol is effective at inducing and maintaining response and remission in Japanese patients with Crohn’s disease: Results from induction and maintenance studies. Gut. 2009; Vol. 58:A170. ">Ogata 2009</a>, and CRP and IBDQ data from <a href="./references#CD012893-bbs2-0004" title="RutgeertsP , SchreiberS , FeaganB , KeiningerDL , O'NeilL , FedorakRN . Certolizumab pegol, a monthly subcutaneously administered Fc‐free anti‐TNFalpha, improves health‐related quality of life in patients with moderate to severe Crohn's disease. International Journal of Colorectal Disease2008;23(3):289‐96. SchreiberS , RutgeertsP , FedorakR , Khaliq‐KareemiM , KammMA , PatelJ , et al. CDP870, a humanized anti‐TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease (CD). Gastroenterology. 2003; Vol. 124:A61. SchreiberS , RutgeertsP , FedorakRN , Khaliq‐KareemiM , KammMA , BoivinM , et al. A randomized, placebo‐controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology2005;129(3):807‐18. ">Schreiber 2005</a>, <a href="./references#CD012893-bbs2-0002" title="NCT00152490 . A study to test the effect of CDP870 in the treatment of Crohn's disease over 26 weeks, comparing CDP870 to a dummy drug (placebo). https://clinicaltrials.gov/ct2/show/NCT00152490. SandbornWJ , FeaganBG , HoniballPJ , RutgeertsP , MasonD , BloomfieldR , et al. Certolizumab pegol for the treatment of Crohn's disease. New England Journal of Medicine2007;357(3):228‐38. SandbornWJ , FeaganBG , StoinovS , HoniballPJ , RutgeertsP , McColmJA . Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26‐week, placebo controlled phase III study (PRECiSE 1). Gastroenterology. 2006; Vol. 130:A107‐8. ">Sandborn 2007</a>, <a href="./references#CD012893-bbs2-0001" title="NCT00291668 . Clinical study of CDP870/Certolizumab Pegol in patients with active Crohn's disease. https://clinicaltrials.gov/ct2/show/study/NCT00291668. OgataH , ItoH , MotoyaS , TakazoeM , SuzukiY , MatsumotoT , et al. Certolizumab pegol is effective at inducing and maintaining response and remission in Japanese patients with Crohn’s disease: Results from induction and maintenance studies. Gut. 2009; Vol. 58:A170. ">Ogata 2009</a>, and <a href="./references#CD012893-bbs2-0003" title="EUCTR‐001913‐41 . A phase IIIb, multinational, randomized, double‐blind, placebo‐controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti‐TNF‐alpha monoclonal antibody, administered subcutaneously at weeks 0, 2 and 4 in subjects with moderately to severely active Crohn’s disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=2007‐001913‐41. NCT00552058 . Study to evaluate efficacy and safety of certolizumab pegol for induction of remission in patients with Crohn's disease. https://ClinicalTrials.gov/show/NCT00552058. SandbornW , SchreiberS , FeaganB , RutgeertsP , YounesZ , BloomfieldR , et al. Induction therapy with certolizumab pegol in patients with moderate to severe Crohn's disease: a placebo‐controlled trial. American Journal of Gastroenterology. 2010; Vol. 105:S419. SandbornWJ , SchreiberS , FeaganBG , RutgeertsP , YounesZH , BloomfieldR , et al. Certolizumab pegol for active Crohn's disease: a placebo‐controlled, randomized trial. Clinical Gastroenterology &amp; Hepatology2011;9(8):670‐8. ">Sandborn 2011</a>. We confirmed via the UCB Inc website (https://www.ucb.com/our‐science/Our‐clinical‐studies/cimzia‐certolizumab‐pegol) that all RCTs conducted by UCB Inc were included in this review. </p> </section> <section id="CD012893-sec-0064"> <h4 class="title">Excluded studies</h4> <p>The characteristics of excluded studies by full‐text assessment are shown in the <a href="./references#CD012893-sec-0099" title="">Characteristics of excluded studies</a> table. We found no ongoing studies. </p> </section> </section> <section id="CD012893-sec-0065"> <h3 class="title">Risk of bias in included studies</h3> <p><a href="#CD012893-fig-0002">Figure 2</a> and <a href="#CD012893-fig-0003">Figure 3</a> report a summary of risk of bias in the included studies. </p> <div class="figure" id="CD012893-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012893-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD012893-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012893-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD012893-sec-0066"> <h4 class="title">Allocation</h4> <p>Centralized randomization schemes with randomization code were used in all studies. Therefore, we considered all studies to be at low risk of selection bias. </p> </section> <section id="CD012893-sec-0067"> <h4 class="title">Blinding</h4> <p><a href="./references#CD012893-bbs2-0004" title="RutgeertsP , SchreiberS , FeaganB , KeiningerDL , O'NeilL , FedorakRN . Certolizumab pegol, a monthly subcutaneously administered Fc‐free anti‐TNFalpha, improves health‐related quality of life in patients with moderate to severe Crohn's disease. International Journal of Colorectal Disease2008;23(3):289‐96. SchreiberS , RutgeertsP , FedorakR , Khaliq‐KareemiM , KammMA , PatelJ , et al. CDP870, a humanized anti‐TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease (CD). Gastroenterology. 2003; Vol. 124:A61. SchreiberS , RutgeertsP , FedorakRN , Khaliq‐KareemiM , KammMA , BoivinM , et al. A randomized, placebo‐controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology2005;129(3):807‐18. ">Schreiber 2005</a> used a placebo that did not have the same color or viscosity of CZP, and patients may have been able to distinguish between CZP and the placebo. Moreover, outcomes were assessed based on patients' daily diaries. Therefore, we considered this study to have high risk of performance and detection bias. The other three studies used an identical placebo and were considered as low risk of bias regarding both performance and detection bias (<a href="./references#CD012893-bbs2-0001" title="NCT00291668 . Clinical study of CDP870/Certolizumab Pegol in patients with active Crohn's disease. https://clinicaltrials.gov/ct2/show/study/NCT00291668. OgataH , ItoH , MotoyaS , TakazoeM , SuzukiY , MatsumotoT , et al. Certolizumab pegol is effective at inducing and maintaining response and remission in Japanese patients with Crohn’s disease: Results from induction and maintenance studies. Gut. 2009; Vol. 58:A170. ">Ogata 2009</a>;<a href="./references#CD012893-bbs2-0002" title="NCT00152490 . A study to test the effect of CDP870 in the treatment of Crohn's disease over 26 weeks, comparing CDP870 to a dummy drug (placebo). https://clinicaltrials.gov/ct2/show/NCT00152490. SandbornWJ , FeaganBG , HoniballPJ , RutgeertsP , MasonD , BloomfieldR , et al. Certolizumab pegol for the treatment of Crohn's disease. New England Journal of Medicine2007;357(3):228‐38. SandbornWJ , FeaganBG , StoinovS , HoniballPJ , RutgeertsP , McColmJA . Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26‐week, placebo controlled phase III study (PRECiSE 1). Gastroenterology. 2006; Vol. 130:A107‐8. ">Sandborn 2007</a>; <a href="./references#CD012893-bbs2-0003" title="EUCTR‐001913‐41 . A phase IIIb, multinational, randomized, double‐blind, placebo‐controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti‐TNF‐alpha monoclonal antibody, administered subcutaneously at weeks 0, 2 and 4 in subjects with moderately to severely active Crohn’s disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=2007‐001913‐41. NCT00552058 . Study to evaluate efficacy and safety of certolizumab pegol for induction of remission in patients with Crohn's disease. https://ClinicalTrials.gov/show/NCT00552058. SandbornW , SchreiberS , FeaganB , RutgeertsP , YounesZ , BloomfieldR , et al. Induction therapy with certolizumab pegol in patients with moderate to severe Crohn's disease: a placebo‐controlled trial. American Journal of Gastroenterology. 2010; Vol. 105:S419. SandbornWJ , SchreiberS , FeaganBG , RutgeertsP , YounesZH , BloomfieldR , et al. Certolizumab pegol for active Crohn's disease: a placebo‐controlled, randomized trial. Clinical Gastroenterology &amp; Hepatology2011;9(8):670‐8. ">Sandborn 2011</a>). </p> </section> <section id="CD012893-sec-0068"> <h4 class="title">Incomplete outcome data</h4> <p>The proportion of loss to follow‐up was less than 2% and was balanced between CZP and placebo in all studies. Therefore, we rated all studies as low risk of attrition bias. </p> </section> <section id="CD012893-sec-0069"> <h4 class="title">Selective reporting</h4> <p>All of the studies reported our prespecified outcomes properly. Therefore, all studies were rated as having low risk of reporting bias. </p> </section> <section id="CD012893-sec-0070"> <h4 class="title">Other potential sources of bias</h4> <p>We did not find any other potential sources of bias in all studies. Therefore, we rated all studies as having low risk of other potential sources of bias </p> </section> </section> <section id="CD012893-sec-0071"> <h3 class="title" id="CD012893-sec-0071">Effects of interventions</h3> <p>See: <a href="./full#CD012893-tbl-0001"><b>Summary of findings for the main comparison</b> Certolizumab pegol compared to placebo for induction of remission in Crohn's disease</a> </p> <section id="CD012893-sec-0072"> <h4 class="title">Main comparison</h4> <p>See Summary of findings table 1: Certolizumab pegol compared to placebo for induction of remission in Crohn’s disease. </p> <p>Clinical remission at week 8, the only primary outcome in this review, was assessed in four studies involving 1485 CD patients (<a href="./references#CD012893-bbs2-0001" title="NCT00291668 . Clinical study of CDP870/Certolizumab Pegol in patients with active Crohn's disease. https://clinicaltrials.gov/ct2/show/study/NCT00291668. OgataH , ItoH , MotoyaS , TakazoeM , SuzukiY , MatsumotoT , et al. Certolizumab pegol is effective at inducing and maintaining response and remission in Japanese patients with Crohn’s disease: Results from induction and maintenance studies. Gut. 2009; Vol. 58:A170. ">Ogata 2009</a>; <a href="./references#CD012893-bbs2-0002" title="NCT00152490 . A study to test the effect of CDP870 in the treatment of Crohn's disease over 26 weeks, comparing CDP870 to a dummy drug (placebo). https://clinicaltrials.gov/ct2/show/NCT00152490. SandbornWJ , FeaganBG , HoniballPJ , RutgeertsP , MasonD , BloomfieldR , et al. Certolizumab pegol for the treatment of Crohn's disease. New England Journal of Medicine2007;357(3):228‐38. SandbornWJ , FeaganBG , StoinovS , HoniballPJ , RutgeertsP , McColmJA . Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26‐week, placebo controlled phase III study (PRECiSE 1). Gastroenterology. 2006; Vol. 130:A107‐8. ">Sandborn 2007</a>; <a href="./references#CD012893-bbs2-0003" title="EUCTR‐001913‐41 . A phase IIIb, multinational, randomized, double‐blind, placebo‐controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti‐TNF‐alpha monoclonal antibody, administered subcutaneously at weeks 0, 2 and 4 in subjects with moderately to severely active Crohn’s disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=2007‐001913‐41. NCT00552058 . Study to evaluate efficacy and safety of certolizumab pegol for induction of remission in patients with Crohn's disease. https://ClinicalTrials.gov/show/NCT00552058. SandbornW , SchreiberS , FeaganB , RutgeertsP , YounesZ , BloomfieldR , et al. Induction therapy with certolizumab pegol in patients with moderate to severe Crohn's disease: a placebo‐controlled trial. American Journal of Gastroenterology. 2010; Vol. 105:S419. SandbornWJ , SchreiberS , FeaganBG , RutgeertsP , YounesZH , BloomfieldR , et al. Certolizumab pegol for active Crohn's disease: a placebo‐controlled, randomized trial. Clinical Gastroenterology &amp; Hepatology2011;9(8):670‐8. ">Sandborn 2011</a>; <a href="./references#CD012893-bbs2-0004" title="RutgeertsP , SchreiberS , FeaganB , KeiningerDL , O'NeilL , FedorakRN . Certolizumab pegol, a monthly subcutaneously administered Fc‐free anti‐TNFalpha, improves health‐related quality of life in patients with moderate to severe Crohn's disease. International Journal of Colorectal Disease2008;23(3):289‐96. SchreiberS , RutgeertsP , FedorakR , Khaliq‐KareemiM , KammMA , PatelJ , et al. CDP870, a humanized anti‐TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease (CD). Gastroenterology. 2003; Vol. 124:A61. SchreiberS , RutgeertsP , FedorakRN , Khaliq‐KareemiM , KammMA , BoivinM , et al. A randomized, placebo‐controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology2005;129(3):807‐18. ">Schreiber 2005</a>). In fact, we could not obtain week eight clinical remission data for two studies involving 533 CD patients (<a href="./references#CD012893-bbs2-0001" title="NCT00291668 . Clinical study of CDP870/Certolizumab Pegol in patients with active Crohn's disease. https://clinicaltrials.gov/ct2/show/study/NCT00291668. OgataH , ItoH , MotoyaS , TakazoeM , SuzukiY , MatsumotoT , et al. Certolizumab pegol is effective at inducing and maintaining response and remission in Japanese patients with Crohn’s disease: Results from induction and maintenance studies. Gut. 2009; Vol. 58:A170. ">Ogata 2009</a>; <a href="./references#CD012893-bbs2-0003" title="EUCTR‐001913‐41 . A phase IIIb, multinational, randomized, double‐blind, placebo‐controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti‐TNF‐alpha monoclonal antibody, administered subcutaneously at weeks 0, 2 and 4 in subjects with moderately to severely active Crohn’s disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=2007‐001913‐41. NCT00552058 . Study to evaluate efficacy and safety of certolizumab pegol for induction of remission in patients with Crohn's disease. https://ClinicalTrials.gov/show/NCT00552058. SandbornW , SchreiberS , FeaganB , RutgeertsP , YounesZ , BloomfieldR , et al. Induction therapy with certolizumab pegol in patients with moderate to severe Crohn's disease: a placebo‐controlled trial. American Journal of Gastroenterology. 2010; Vol. 105:S419. SandbornWJ , SchreiberS , FeaganBG , RutgeertsP , YounesZH , BloomfieldR , et al. Certolizumab pegol for active Crohn's disease: a placebo‐controlled, randomized trial. Clinical Gastroenterology &amp; Hepatology2011;9(8):670‐8. ">Sandborn 2011</a>). As defined in our protocol, we used week six clinical remission data from <a href="./references#CD012893-bbs2-0001" title="NCT00291668 . Clinical study of CDP870/Certolizumab Pegol in patients with active Crohn's disease. https://clinicaltrials.gov/ct2/show/study/NCT00291668. OgataH , ItoH , MotoyaS , TakazoeM , SuzukiY , MatsumotoT , et al. Certolizumab pegol is effective at inducing and maintaining response and remission in Japanese patients with Crohn’s disease: Results from induction and maintenance studies. Gut. 2009; Vol. 58:A170. ">Ogata 2009</a> and <a href="./references#CD012893-bbs2-0003" title="EUCTR‐001913‐41 . A phase IIIb, multinational, randomized, double‐blind, placebo‐controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti‐TNF‐alpha monoclonal antibody, administered subcutaneously at weeks 0, 2 and 4 in subjects with moderately to severely active Crohn’s disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=2007‐001913‐41. NCT00552058 . Study to evaluate efficacy and safety of certolizumab pegol for induction of remission in patients with Crohn's disease. https://ClinicalTrials.gov/show/NCT00552058. SandbornW , SchreiberS , FeaganB , RutgeertsP , YounesZ , BloomfieldR , et al. Induction therapy with certolizumab pegol in patients with moderate to severe Crohn's disease: a placebo‐controlled trial. American Journal of Gastroenterology. 2010; Vol. 105:S419. SandbornWJ , SchreiberS , FeaganBG , RutgeertsP , YounesZH , BloomfieldR , et al. Certolizumab pegol for active Crohn's disease: a placebo‐controlled, randomized trial. Clinical Gastroenterology &amp; Hepatology2011;9(8):670‐8. ">Sandborn 2011</a>, and these data were combined with week eight data from the other two studies involving 952 CD patients (<a href="./references#CD012893-bbs2-0002" title="NCT00152490 . A study to test the effect of CDP870 in the treatment of Crohn's disease over 26 weeks, comparing CDP870 to a dummy drug (placebo). https://clinicaltrials.gov/ct2/show/NCT00152490. SandbornWJ , FeaganBG , HoniballPJ , RutgeertsP , MasonD , BloomfieldR , et al. Certolizumab pegol for the treatment of Crohn's disease. New England Journal of Medicine2007;357(3):228‐38. SandbornWJ , FeaganBG , StoinovS , HoniballPJ , RutgeertsP , McColmJA . Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26‐week, placebo controlled phase III study (PRECiSE 1). Gastroenterology. 2006; Vol. 130:A107‐8. ">Sandborn 2007</a>; <a href="./references#CD012893-bbs2-0004" title="RutgeertsP , SchreiberS , FeaganB , KeiningerDL , O'NeilL , FedorakRN . Certolizumab pegol, a monthly subcutaneously administered Fc‐free anti‐TNFalpha, improves health‐related quality of life in patients with moderate to severe Crohn's disease. International Journal of Colorectal Disease2008;23(3):289‐96. SchreiberS , RutgeertsP , FedorakR , Khaliq‐KareemiM , KammMA , PatelJ , et al. CDP870, a humanized anti‐TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease (CD). Gastroenterology. 2003; Vol. 124:A61. SchreiberS , RutgeertsP , FedorakRN , Khaliq‐KareemiM , KammMA , BoivinM , et al. A randomized, placebo‐controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology2005;129(3):807‐18. ">Schreiber 2005</a>). Heterogeneity was low ( I² = 2%). Clinical remission was achieved in 26.9% (225/835) and 19.8% (129/650) in the CZP and placebo groups, respectively. In the meta‐analysis using the Mantel‐Haenszel random‐effects method, patients treated with CZP (100 mg to 400 mg every 2 to 4 weeks) were significantly more likely to achieve clinical remission at week 8 than those treated with placebo (RR 1.36, 95% CI 1.11 to 1.66; see <a href="#CD012893-fig-0004">Figure 4</a>). The certainty of evidence was moderate according to the GRADE system. </p> <div class="figure" id="CD012893-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Certolizumab pegol versus placebo, outcome: 1.1 Clinical remission at week 8." data-id="CD012893-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Certolizumab pegol versus placebo, outcome: 1.1 Clinical remission at week 8. </p> </div> </div> </div> <p>Clinical response at week 8, a secondary outcome in this review, was assessed in four studies involving 1485 CD patients (<a href="./references#CD012893-bbs2-0001" title="NCT00291668 . Clinical study of CDP870/Certolizumab Pegol in patients with active Crohn's disease. https://clinicaltrials.gov/ct2/show/study/NCT00291668. OgataH , ItoH , MotoyaS , TakazoeM , SuzukiY , MatsumotoT , et al. Certolizumab pegol is effective at inducing and maintaining response and remission in Japanese patients with Crohn’s disease: Results from induction and maintenance studies. Gut. 2009; Vol. 58:A170. ">Ogata 2009</a>; <a href="./references#CD012893-bbs2-0002" title="NCT00152490 . A study to test the effect of CDP870 in the treatment of Crohn's disease over 26 weeks, comparing CDP870 to a dummy drug (placebo). https://clinicaltrials.gov/ct2/show/NCT00152490. SandbornWJ , FeaganBG , HoniballPJ , RutgeertsP , MasonD , BloomfieldR , et al. Certolizumab pegol for the treatment of Crohn's disease. New England Journal of Medicine2007;357(3):228‐38. SandbornWJ , FeaganBG , StoinovS , HoniballPJ , RutgeertsP , McColmJA . Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26‐week, placebo controlled phase III study (PRECiSE 1). Gastroenterology. 2006; Vol. 130:A107‐8. ">Sandborn 2007</a>; <a href="./references#CD012893-bbs2-0003" title="EUCTR‐001913‐41 . A phase IIIb, multinational, randomized, double‐blind, placebo‐controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti‐TNF‐alpha monoclonal antibody, administered subcutaneously at weeks 0, 2 and 4 in subjects with moderately to severely active Crohn’s disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=2007‐001913‐41. NCT00552058 . Study to evaluate efficacy and safety of certolizumab pegol for induction of remission in patients with Crohn's disease. https://ClinicalTrials.gov/show/NCT00552058. SandbornW , SchreiberS , FeaganB , RutgeertsP , YounesZ , BloomfieldR , et al. Induction therapy with certolizumab pegol in patients with moderate to severe Crohn's disease: a placebo‐controlled trial. American Journal of Gastroenterology. 2010; Vol. 105:S419. SandbornWJ , SchreiberS , FeaganBG , RutgeertsP , YounesZH , BloomfieldR , et al. Certolizumab pegol for active Crohn's disease: a placebo‐controlled, randomized trial. Clinical Gastroenterology &amp; Hepatology2011;9(8):670‐8. ">Sandborn 2011</a>; <a href="./references#CD012893-bbs2-0004" title="RutgeertsP , SchreiberS , FeaganB , KeiningerDL , O'NeilL , FedorakRN . Certolizumab pegol, a monthly subcutaneously administered Fc‐free anti‐TNFalpha, improves health‐related quality of life in patients with moderate to severe Crohn's disease. International Journal of Colorectal Disease2008;23(3):289‐96. SchreiberS , RutgeertsP , FedorakR , Khaliq‐KareemiM , KammMA , PatelJ , et al. CDP870, a humanized anti‐TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease (CD). Gastroenterology. 2003; Vol. 124:A61. SchreiberS , RutgeertsP , FedorakRN , Khaliq‐KareemiM , KammMA , BoivinM , et al. A randomized, placebo‐controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology2005;129(3):807‐18. ">Schreiber 2005</a>). Clinical response was achieved in 40.2% (336/835) and 30.9% (201/650) in the CZP and placebo groups respectively. In the meta‐analysis using the Mantel‐Haenszel random‐effects method, patients treated with CZP were significantly more likely to achieve clinical response at week 8 than those with treated with placebo (RR 1.29, 95% CI 1.09 to 1.53; see <a href="#CD012893-fig-0005">Figure 5</a>). The certainty of evidence was moderate according to the GRADE system. </p> <div class="figure" id="CD012893-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Certolizumab pegol versus placebo, outcome: 1.2 Clinical response at week 8." data-id="CD012893-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Certolizumab pegol versus placebo, outcome: 1.2 Clinical response at week 8. </p> </div> </div> </div> <p>Serious adverse events, a secondary outcome in this review, were assessed in four studies involving 1485 CD patients (<a href="./references#CD012893-bbs2-0001" title="NCT00291668 . Clinical study of CDP870/Certolizumab Pegol in patients with active Crohn's disease. https://clinicaltrials.gov/ct2/show/study/NCT00291668. OgataH , ItoH , MotoyaS , TakazoeM , SuzukiY , MatsumotoT , et al. Certolizumab pegol is effective at inducing and maintaining response and remission in Japanese patients with Crohn’s disease: Results from induction and maintenance studies. Gut. 2009; Vol. 58:A170. ">Ogata 2009</a>; <a href="./references#CD012893-bbs2-0002" title="NCT00152490 . A study to test the effect of CDP870 in the treatment of Crohn's disease over 26 weeks, comparing CDP870 to a dummy drug (placebo). https://clinicaltrials.gov/ct2/show/NCT00152490. SandbornWJ , FeaganBG , HoniballPJ , RutgeertsP , MasonD , BloomfieldR , et al. Certolizumab pegol for the treatment of Crohn's disease. New England Journal of Medicine2007;357(3):228‐38. SandbornWJ , FeaganBG , StoinovS , HoniballPJ , RutgeertsP , McColmJA . Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26‐week, placebo controlled phase III study (PRECiSE 1). Gastroenterology. 2006; Vol. 130:A107‐8. ">Sandborn 2007</a>; <a href="./references#CD012893-bbs2-0003" title="EUCTR‐001913‐41 . A phase IIIb, multinational, randomized, double‐blind, placebo‐controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti‐TNF‐alpha monoclonal antibody, administered subcutaneously at weeks 0, 2 and 4 in subjects with moderately to severely active Crohn’s disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=2007‐001913‐41. NCT00552058 . Study to evaluate efficacy and safety of certolizumab pegol for induction of remission in patients with Crohn's disease. https://ClinicalTrials.gov/show/NCT00552058. SandbornW , SchreiberS , FeaganB , RutgeertsP , YounesZ , BloomfieldR , et al. Induction therapy with certolizumab pegol in patients with moderate to severe Crohn's disease: a placebo‐controlled trial. American Journal of Gastroenterology. 2010; Vol. 105:S419. SandbornWJ , SchreiberS , FeaganBG , RutgeertsP , YounesZH , BloomfieldR , et al. Certolizumab pegol for active Crohn's disease: a placebo‐controlled, randomized trial. Clinical Gastroenterology &amp; Hepatology2011;9(8):670‐8. ">Sandborn 2011</a>; <a href="./references#CD012893-bbs2-0004" title="RutgeertsP , SchreiberS , FeaganB , KeiningerDL , O'NeilL , FedorakRN . Certolizumab pegol, a monthly subcutaneously administered Fc‐free anti‐TNFalpha, improves health‐related quality of life in patients with moderate to severe Crohn's disease. International Journal of Colorectal Disease2008;23(3):289‐96. SchreiberS , RutgeertsP , FedorakR , Khaliq‐KareemiM , KammMA , PatelJ , et al. CDP870, a humanized anti‐TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease (CD). Gastroenterology. 2003; Vol. 124:A61. SchreiberS , RutgeertsP , FedorakRN , Khaliq‐KareemiM , KammMA , BoivinM , et al. A randomized, placebo‐controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology2005;129(3):807‐18. ">Schreiber 2005</a>). Serious adverse events such as worsening CD, various infections, and malignancy occurred in 8.7% (73/835) and 6.2% (40/650) in CZP and placebo, respectively. In the meta‐analysis using the Mantel‐Haenszel random‐effects method, it is uncertain whether the risk of serious adverse events differs between CZP and placebo (RR 1.35, 95% CI: 0.93 to 1.97; see <a href="#CD012893-fig-0006">Figure 6</a>). According to GRADE system, the certainty of evidence was moderate because the number of events was low, and showed imprecision in the results. </p> <div class="figure" id="CD012893-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Certolizumab pegol versus placebo, outcome: 1.6 Serious adverse events." data-id="CD012893-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Certolizumab pegol versus placebo, outcome: 1.6 Serious adverse events. </p> </div> </div> </div> </section> <section id="CD012893-sec-0073"> <h4 class="title">Efficacy outcomes</h4> <p>The log scales of the geometric mean CRP ratio between baseline and week 8 were assessed in four studies involving 1271 CD patients (<a href="./references#CD012893-bbs2-0001" title="NCT00291668 . Clinical study of CDP870/Certolizumab Pegol in patients with active Crohn's disease. https://clinicaltrials.gov/ct2/show/study/NCT00291668. OgataH , ItoH , MotoyaS , TakazoeM , SuzukiY , MatsumotoT , et al. Certolizumab pegol is effective at inducing and maintaining response and remission in Japanese patients with Crohn’s disease: Results from induction and maintenance studies. Gut. 2009; Vol. 58:A170. ">Ogata 2009</a>; <a href="./references#CD012893-bbs2-0002" title="NCT00152490 . A study to test the effect of CDP870 in the treatment of Crohn's disease over 26 weeks, comparing CDP870 to a dummy drug (placebo). https://clinicaltrials.gov/ct2/show/NCT00152490. SandbornWJ , FeaganBG , HoniballPJ , RutgeertsP , MasonD , BloomfieldR , et al. Certolizumab pegol for the treatment of Crohn's disease. New England Journal of Medicine2007;357(3):228‐38. SandbornWJ , FeaganBG , StoinovS , HoniballPJ , RutgeertsP , McColmJA . Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26‐week, placebo controlled phase III study (PRECiSE 1). Gastroenterology. 2006; Vol. 130:A107‐8. ">Sandborn 2007</a>; <a href="./references#CD012893-bbs2-0003" title="EUCTR‐001913‐41 . A phase IIIb, multinational, randomized, double‐blind, placebo‐controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti‐TNF‐alpha monoclonal antibody, administered subcutaneously at weeks 0, 2 and 4 in subjects with moderately to severely active Crohn’s disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=2007‐001913‐41. NCT00552058 . Study to evaluate efficacy and safety of certolizumab pegol for induction of remission in patients with Crohn's disease. https://ClinicalTrials.gov/show/NCT00552058. SandbornW , SchreiberS , FeaganB , RutgeertsP , YounesZ , BloomfieldR , et al. Induction therapy with certolizumab pegol in patients with moderate to severe Crohn's disease: a placebo‐controlled trial. American Journal of Gastroenterology. 2010; Vol. 105:S419. SandbornWJ , SchreiberS , FeaganBG , RutgeertsP , YounesZH , BloomfieldR , et al. Certolizumab pegol for active Crohn's disease: a placebo‐controlled, randomized trial. Clinical Gastroenterology &amp; Hepatology2011;9(8):670‐8. ">Sandborn 2011</a>; <a href="./references#CD012893-bbs2-0004" title="RutgeertsP , SchreiberS , FeaganB , KeiningerDL , O'NeilL , FedorakRN . Certolizumab pegol, a monthly subcutaneously administered Fc‐free anti‐TNFalpha, improves health‐related quality of life in patients with moderate to severe Crohn's disease. International Journal of Colorectal Disease2008;23(3):289‐96. SchreiberS , RutgeertsP , FedorakR , Khaliq‐KareemiM , KammMA , PatelJ , et al. CDP870, a humanized anti‐TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease (CD). Gastroenterology. 2003; Vol. 124:A61. SchreiberS , RutgeertsP , FedorakRN , Khaliq‐KareemiM , KammMA , BoivinM , et al. A randomized, placebo‐controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology2005;129(3):807‐18. ">Schreiber 2005</a>). In the meta‐analysis using the inverse variance random‐effects method, patients treated with CZP were significantly more likely to have improvement in CRP at week 8 than those treated with placebo (MD ‐0.37, 95% CI ‐0.49 to ‐0.24). </p> <p>The mean change in IBDQ score from baseline was assessed in four studies involving 1315 CD patients (<a href="./references#CD012893-bbs2-0001" title="NCT00291668 . Clinical study of CDP870/Certolizumab Pegol in patients with active Crohn's disease. https://clinicaltrials.gov/ct2/show/study/NCT00291668. OgataH , ItoH , MotoyaS , TakazoeM , SuzukiY , MatsumotoT , et al. Certolizumab pegol is effective at inducing and maintaining response and remission in Japanese patients with Crohn’s disease: Results from induction and maintenance studies. Gut. 2009; Vol. 58:A170. ">Ogata 2009</a>; <a href="./references#CD012893-bbs2-0002" title="NCT00152490 . A study to test the effect of CDP870 in the treatment of Crohn's disease over 26 weeks, comparing CDP870 to a dummy drug (placebo). https://clinicaltrials.gov/ct2/show/NCT00152490. SandbornWJ , FeaganBG , HoniballPJ , RutgeertsP , MasonD , BloomfieldR , et al. Certolizumab pegol for the treatment of Crohn's disease. New England Journal of Medicine2007;357(3):228‐38. SandbornWJ , FeaganBG , StoinovS , HoniballPJ , RutgeertsP , McColmJA . Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26‐week, placebo controlled phase III study (PRECiSE 1). Gastroenterology. 2006; Vol. 130:A107‐8. ">Sandborn 2007</a>; <a href="./references#CD012893-bbs2-0003" title="EUCTR‐001913‐41 . A phase IIIb, multinational, randomized, double‐blind, placebo‐controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti‐TNF‐alpha monoclonal antibody, administered subcutaneously at weeks 0, 2 and 4 in subjects with moderately to severely active Crohn’s disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=2007‐001913‐41. NCT00552058 . Study to evaluate efficacy and safety of certolizumab pegol for induction of remission in patients with Crohn's disease. https://ClinicalTrials.gov/show/NCT00552058. SandbornW , SchreiberS , FeaganB , RutgeertsP , YounesZ , BloomfieldR , et al. Induction therapy with certolizumab pegol in patients with moderate to severe Crohn's disease: a placebo‐controlled trial. American Journal of Gastroenterology. 2010; Vol. 105:S419. SandbornWJ , SchreiberS , FeaganBG , RutgeertsP , YounesZH , BloomfieldR , et al. Certolizumab pegol for active Crohn's disease: a placebo‐controlled, randomized trial. Clinical Gastroenterology &amp; Hepatology2011;9(8):670‐8. ">Sandborn 2011</a>; <a href="./references#CD012893-bbs2-0004" title="RutgeertsP , SchreiberS , FeaganB , KeiningerDL , O'NeilL , FedorakRN . Certolizumab pegol, a monthly subcutaneously administered Fc‐free anti‐TNFalpha, improves health‐related quality of life in patients with moderate to severe Crohn's disease. International Journal of Colorectal Disease2008;23(3):289‐96. SchreiberS , RutgeertsP , FedorakR , Khaliq‐KareemiM , KammMA , PatelJ , et al. CDP870, a humanized anti‐TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease (CD). Gastroenterology. 2003; Vol. 124:A61. SchreiberS , RutgeertsP , FedorakRN , Khaliq‐KareemiM , KammMA , BoivinM , et al. A randomized, placebo‐controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology2005;129(3):807‐18. ">Schreiber 2005</a>). In the meta‐analysis using the inverse variance random‐effects method, CZP did not appear to make a clear difference in IBDQ at week 8 (MD 2.12, 95% CI ‐1.27 to 5.50). </p> <p>We did not find any eligible studies assessing endoscopic improvement or fistula closure.</p> </section> <section id="CD012893-sec-0074"> <h4 class="title">Safety outcomes</h4> <p>Adverse events were assessed in four studies involving 1485 CD patients (<a href="./references#CD012893-bbs2-0001" title="NCT00291668 . Clinical study of CDP870/Certolizumab Pegol in patients with active Crohn's disease. https://clinicaltrials.gov/ct2/show/study/NCT00291668. OgataH , ItoH , MotoyaS , TakazoeM , SuzukiY , MatsumotoT , et al. Certolizumab pegol is effective at inducing and maintaining response and remission in Japanese patients with Crohn’s disease: Results from induction and maintenance studies. Gut. 2009; Vol. 58:A170. ">Ogata 2009</a>; <a href="./references#CD012893-bbs2-0002" title="NCT00152490 . A study to test the effect of CDP870 in the treatment of Crohn's disease over 26 weeks, comparing CDP870 to a dummy drug (placebo). https://clinicaltrials.gov/ct2/show/NCT00152490. SandbornWJ , FeaganBG , HoniballPJ , RutgeertsP , MasonD , BloomfieldR , et al. Certolizumab pegol for the treatment of Crohn's disease. New England Journal of Medicine2007;357(3):228‐38. SandbornWJ , FeaganBG , StoinovS , HoniballPJ , RutgeertsP , McColmJA . Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26‐week, placebo controlled phase III study (PRECiSE 1). Gastroenterology. 2006; Vol. 130:A107‐8. ">Sandborn 2007</a>; <a href="./references#CD012893-bbs2-0003" title="EUCTR‐001913‐41 . A phase IIIb, multinational, randomized, double‐blind, placebo‐controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti‐TNF‐alpha monoclonal antibody, administered subcutaneously at weeks 0, 2 and 4 in subjects with moderately to severely active Crohn’s disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=2007‐001913‐41. NCT00552058 . Study to evaluate efficacy and safety of certolizumab pegol for induction of remission in patients with Crohn's disease. https://ClinicalTrials.gov/show/NCT00552058. SandbornW , SchreiberS , FeaganB , RutgeertsP , YounesZ , BloomfieldR , et al. Induction therapy with certolizumab pegol in patients with moderate to severe Crohn's disease: a placebo‐controlled trial. American Journal of Gastroenterology. 2010; Vol. 105:S419. SandbornWJ , SchreiberS , FeaganBG , RutgeertsP , YounesZH , BloomfieldR , et al. Certolizumab pegol for active Crohn's disease: a placebo‐controlled, randomized trial. Clinical Gastroenterology &amp; Hepatology2011;9(8):670‐8. ">Sandborn 2011</a>; <a href="./references#CD012893-bbs2-0004" title="RutgeertsP , SchreiberS , FeaganB , KeiningerDL , O'NeilL , FedorakRN . Certolizumab pegol, a monthly subcutaneously administered Fc‐free anti‐TNFalpha, improves health‐related quality of life in patients with moderate to severe Crohn's disease. International Journal of Colorectal Disease2008;23(3):289‐96. SchreiberS , RutgeertsP , FedorakR , Khaliq‐KareemiM , KammMA , PatelJ , et al. CDP870, a humanized anti‐TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease (CD). Gastroenterology. 2003; Vol. 124:A61. SchreiberS , RutgeertsP , FedorakRN , Khaliq‐KareemiM , KammMA , BoivinM , et al. A randomized, placebo‐controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology2005;129(3):807‐18. ">Schreiber 2005</a>). In the meta‐analysis using the Mantel‐Haenszel random‐effects method, CZP did not appear to make any clear difference in the risk of having adverse events (RR 1.03, 95% CI 0.97 to 1.10). </p> <p>Withdrawals due to adverse events were assessed in four studies involving 1485 CD patients (<a href="./references#CD012893-bbs2-0001" title="NCT00291668 . Clinical study of CDP870/Certolizumab Pegol in patients with active Crohn's disease. https://clinicaltrials.gov/ct2/show/study/NCT00291668. OgataH , ItoH , MotoyaS , TakazoeM , SuzukiY , MatsumotoT , et al. Certolizumab pegol is effective at inducing and maintaining response and remission in Japanese patients with Crohn’s disease: Results from induction and maintenance studies. Gut. 2009; Vol. 58:A170. ">Ogata 2009</a>; <a href="./references#CD012893-bbs2-0002" title="NCT00152490 . A study to test the effect of CDP870 in the treatment of Crohn's disease over 26 weeks, comparing CDP870 to a dummy drug (placebo). https://clinicaltrials.gov/ct2/show/NCT00152490. SandbornWJ , FeaganBG , HoniballPJ , RutgeertsP , MasonD , BloomfieldR , et al. Certolizumab pegol for the treatment of Crohn's disease. New England Journal of Medicine2007;357(3):228‐38. SandbornWJ , FeaganBG , StoinovS , HoniballPJ , RutgeertsP , McColmJA . Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26‐week, placebo controlled phase III study (PRECiSE 1). Gastroenterology. 2006; Vol. 130:A107‐8. ">Sandborn 2007</a>; <a href="./references#CD012893-bbs2-0003" title="EUCTR‐001913‐41 . A phase IIIb, multinational, randomized, double‐blind, placebo‐controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti‐TNF‐alpha monoclonal antibody, administered subcutaneously at weeks 0, 2 and 4 in subjects with moderately to severely active Crohn’s disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=2007‐001913‐41. NCT00552058 . Study to evaluate efficacy and safety of certolizumab pegol for induction of remission in patients with Crohn's disease. https://ClinicalTrials.gov/show/NCT00552058. SandbornW , SchreiberS , FeaganB , RutgeertsP , YounesZ , BloomfieldR , et al. Induction therapy with certolizumab pegol in patients with moderate to severe Crohn's disease: a placebo‐controlled trial. American Journal of Gastroenterology. 2010; Vol. 105:S419. SandbornWJ , SchreiberS , FeaganBG , RutgeertsP , YounesZH , BloomfieldR , et al. Certolizumab pegol for active Crohn's disease: a placebo‐controlled, randomized trial. Clinical Gastroenterology &amp; Hepatology2011;9(8):670‐8. ">Sandborn 2011</a>; <a href="./references#CD012893-bbs2-0004" title="RutgeertsP , SchreiberS , FeaganB , KeiningerDL , O'NeilL , FedorakRN . Certolizumab pegol, a monthly subcutaneously administered Fc‐free anti‐TNFalpha, improves health‐related quality of life in patients with moderate to severe Crohn's disease. International Journal of Colorectal Disease2008;23(3):289‐96. SchreiberS , RutgeertsP , FedorakR , Khaliq‐KareemiM , KammMA , PatelJ , et al. CDP870, a humanized anti‐TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease (CD). Gastroenterology. 2003; Vol. 124:A61. SchreiberS , RutgeertsP , FedorakRN , Khaliq‐KareemiM , KammMA , BoivinM , et al. A randomized, placebo‐controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology2005;129(3):807‐18. ">Schreiber 2005</a>). In the meta‐analysis using the Mantel‐Haenszel random‐effects method, there was no clear difference between CZP and placebo in the risk of withdrawals due to adverse events (RR 1.01, 95% CI: 0.57 to 1.78). </p> </section> <section id="CD012893-sec-0075"> <h4 class="title">Subgroup analyses</h4> <p>We conducted three prespecified subgroup analyses to evaluate clinical remission at week 8 based on CZP doses, previous treatment with TNF‐α inhibitors, and CRP levels at baseline. We did not conduct a prespecified subgroup analysis based on disease severity because disease severity was similar among all of the included studies. </p> <p>Clinical remission at week 8 with CZP 100 mg was assessed in a study involving 99 CD patients (<a href="./references#CD012893-bbs2-0004" title="RutgeertsP , SchreiberS , FeaganB , KeiningerDL , O'NeilL , FedorakRN . Certolizumab pegol, a monthly subcutaneously administered Fc‐free anti‐TNFalpha, improves health‐related quality of life in patients with moderate to severe Crohn's disease. International Journal of Colorectal Disease2008;23(3):289‐96. SchreiberS , RutgeertsP , FedorakR , Khaliq‐KareemiM , KammMA , PatelJ , et al. CDP870, a humanized anti‐TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease (CD). Gastroenterology. 2003; Vol. 124:A61. SchreiberS , RutgeertsP , FedorakRN , Khaliq‐KareemiM , KammMA , BoivinM , et al. A randomized, placebo‐controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology2005;129(3):807‐18. ">Schreiber 2005</a>). In the meta‐analysis using the Mantel‐Haenszel random‐effects method, it was uncertain whether clinical remission at week 8 differs between CZP 100 mg and placebo (RR 2.48, 95% CI: 0.81 to 7.58). Similarly, it was unclear whether clinical remission at week 8 differs between CZP 200 mg and placebo in 2 studies involving 142 CD patients (RR 1.84, 95% CI: 0.75 to 4.50) (<a href="./references#CD012893-bbs2-0001" title="NCT00291668 . Clinical study of CDP870/Certolizumab Pegol in patients with active Crohn's disease. https://clinicaltrials.gov/ct2/show/study/NCT00291668. OgataH , ItoH , MotoyaS , TakazoeM , SuzukiY , MatsumotoT , et al. Certolizumab pegol is effective at inducing and maintaining response and remission in Japanese patients with Crohn’s disease: Results from induction and maintenance studies. Gut. 2009; Vol. 58:A170. ">Ogata 2009</a>; <a href="./references#CD012893-bbs2-0004" title="RutgeertsP , SchreiberS , FeaganB , KeiningerDL , O'NeilL , FedorakRN . Certolizumab pegol, a monthly subcutaneously administered Fc‐free anti‐TNFalpha, improves health‐related quality of life in patients with moderate to severe Crohn's disease. International Journal of Colorectal Disease2008;23(3):289‐96. SchreiberS , RutgeertsP , FedorakR , Khaliq‐KareemiM , KammMA , PatelJ , et al. CDP870, a humanized anti‐TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease (CD). Gastroenterology. 2003; Vol. 124:A61. SchreiberS , RutgeertsP , FedorakRN , Khaliq‐KareemiM , KammMA , BoivinM , et al. A randomized, placebo‐controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology2005;129(3):807‐18. ">Schreiber 2005</a>). However, patients treated with CZP 400 mg were significantly more likely than placebo participants to achieve clinical remission at week 8 (RR 1.30, 95% CI: 1.06 to 1.60, 4 studies; 1244 CD patients) (<a href="./references#CD012893-bbs2-0001" title="NCT00291668 . Clinical study of CDP870/Certolizumab Pegol in patients with active Crohn's disease. https://clinicaltrials.gov/ct2/show/study/NCT00291668. OgataH , ItoH , MotoyaS , TakazoeM , SuzukiY , MatsumotoT , et al. Certolizumab pegol is effective at inducing and maintaining response and remission in Japanese patients with Crohn’s disease: Results from induction and maintenance studies. Gut. 2009; Vol. 58:A170. ">Ogata 2009</a>; <a href="./references#CD012893-bbs2-0002" title="NCT00152490 . A study to test the effect of CDP870 in the treatment of Crohn's disease over 26 weeks, comparing CDP870 to a dummy drug (placebo). https://clinicaltrials.gov/ct2/show/NCT00152490. SandbornWJ , FeaganBG , HoniballPJ , RutgeertsP , MasonD , BloomfieldR , et al. Certolizumab pegol for the treatment of Crohn's disease. New England Journal of Medicine2007;357(3):228‐38. SandbornWJ , FeaganBG , StoinovS , HoniballPJ , RutgeertsP , McColmJA . Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26‐week, placebo controlled phase III study (PRECiSE 1). Gastroenterology. 2006; Vol. 130:A107‐8. ">Sandborn 2007</a>; <a href="./references#CD012893-bbs2-0003" title="EUCTR‐001913‐41 . A phase IIIb, multinational, randomized, double‐blind, placebo‐controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti‐TNF‐alpha monoclonal antibody, administered subcutaneously at weeks 0, 2 and 4 in subjects with moderately to severely active Crohn’s disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=2007‐001913‐41. NCT00552058 . Study to evaluate efficacy and safety of certolizumab pegol for induction of remission in patients with Crohn's disease. https://ClinicalTrials.gov/show/NCT00552058. SandbornW , SchreiberS , FeaganB , RutgeertsP , YounesZ , BloomfieldR , et al. Induction therapy with certolizumab pegol in patients with moderate to severe Crohn's disease: a placebo‐controlled trial. American Journal of Gastroenterology. 2010; Vol. 105:S419. SandbornWJ , SchreiberS , FeaganBG , RutgeertsP , YounesZH , BloomfieldR , et al. Certolizumab pegol for active Crohn's disease: a placebo‐controlled, randomized trial. Clinical Gastroenterology &amp; Hepatology2011;9(8):670‐8. ">Sandborn 2011</a>; <a href="./references#CD012893-bbs2-0004" title="RutgeertsP , SchreiberS , FeaganB , KeiningerDL , O'NeilL , FedorakRN . Certolizumab pegol, a monthly subcutaneously administered Fc‐free anti‐TNFalpha, improves health‐related quality of life in patients with moderate to severe Crohn's disease. International Journal of Colorectal Disease2008;23(3):289‐96. SchreiberS , RutgeertsP , FedorakR , Khaliq‐KareemiM , KammMA , PatelJ , et al. CDP870, a humanized anti‐TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease (CD). Gastroenterology. 2003; Vol. 124:A61. SchreiberS , RutgeertsP , FedorakRN , Khaliq‐KareemiM , KammMA , BoivinM , et al. A randomized, placebo‐controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology2005;129(3):807‐18. ">Schreiber 2005</a>). We did not conduct a subgroup analysis of patients with CZP ≥ 600 mg because there were no studies using this dose. </p> <p>Clinical remission at week 8 among patients with no previous treatment with TNF‐α inhibitors was assessed in a study involving 439 CD patients (<a href="./references#CD012893-bbs2-0003" title="EUCTR‐001913‐41 . A phase IIIb, multinational, randomized, double‐blind, placebo‐controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti‐TNF‐alpha monoclonal antibody, administered subcutaneously at weeks 0, 2 and 4 in subjects with moderately to severely active Crohn’s disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=2007‐001913‐41. NCT00552058 . Study to evaluate efficacy and safety of certolizumab pegol for induction of remission in patients with Crohn's disease. https://ClinicalTrials.gov/show/NCT00552058. SandbornW , SchreiberS , FeaganB , RutgeertsP , YounesZ , BloomfieldR , et al. Induction therapy with certolizumab pegol in patients with moderate to severe Crohn's disease: a placebo‐controlled trial. American Journal of Gastroenterology. 2010; Vol. 105:S419. SandbornWJ , SchreiberS , FeaganBG , RutgeertsP , YounesZH , BloomfieldR , et al. Certolizumab pegol for active Crohn's disease: a placebo‐controlled, randomized trial. Clinical Gastroenterology &amp; Hepatology2011;9(8):670‐8. ">Sandborn 2011</a>). In the meta‐analysis using the Mantel‐Haenszel random‐effects method, it was uncertain whether clinical remission at week 8 differs between CZP and placebo patients (RR 1.24, 95% CI: 0.91 to 1.69). We did not conduct a subgroup analysis of CD patients who had previous treatment with TNF‐α inhibitors due to lack of data. </p> <p>Clinical remission at week 8 among patients with baseline CRP ≥ 10 mg/L was assessed in 4 studies involving 702 CD patients (<a href="./references#CD012893-bbs2-0001" title="NCT00291668 . Clinical study of CDP870/Certolizumab Pegol in patients with active Crohn's disease. https://clinicaltrials.gov/ct2/show/study/NCT00291668. OgataH , ItoH , MotoyaS , TakazoeM , SuzukiY , MatsumotoT , et al. Certolizumab pegol is effective at inducing and maintaining response and remission in Japanese patients with Crohn’s disease: Results from induction and maintenance studies. Gut. 2009; Vol. 58:A170. ">Ogata 2009</a>; <a href="./references#CD012893-bbs2-0002" title="NCT00152490 . A study to test the effect of CDP870 in the treatment of Crohn's disease over 26 weeks, comparing CDP870 to a dummy drug (placebo). https://clinicaltrials.gov/ct2/show/NCT00152490. SandbornWJ , FeaganBG , HoniballPJ , RutgeertsP , MasonD , BloomfieldR , et al. Certolizumab pegol for the treatment of Crohn's disease. New England Journal of Medicine2007;357(3):228‐38. SandbornWJ , FeaganBG , StoinovS , HoniballPJ , RutgeertsP , McColmJA . Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26‐week, placebo controlled phase III study (PRECiSE 1). Gastroenterology. 2006; Vol. 130:A107‐8. ">Sandborn 2007</a>; <a href="./references#CD012893-bbs2-0003" title="EUCTR‐001913‐41 . A phase IIIb, multinational, randomized, double‐blind, placebo‐controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti‐TNF‐alpha monoclonal antibody, administered subcutaneously at weeks 0, 2 and 4 in subjects with moderately to severely active Crohn’s disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=2007‐001913‐41. NCT00552058 . Study to evaluate efficacy and safety of certolizumab pegol for induction of remission in patients with Crohn's disease. https://ClinicalTrials.gov/show/NCT00552058. SandbornW , SchreiberS , FeaganB , RutgeertsP , YounesZ , BloomfieldR , et al. Induction therapy with certolizumab pegol in patients with moderate to severe Crohn's disease: a placebo‐controlled trial. American Journal of Gastroenterology. 2010; Vol. 105:S419. SandbornWJ , SchreiberS , FeaganBG , RutgeertsP , YounesZH , BloomfieldR , et al. Certolizumab pegol for active Crohn's disease: a placebo‐controlled, randomized trial. Clinical Gastroenterology &amp; Hepatology2011;9(8):670‐8. ">Sandborn 2011</a>; <a href="./references#CD012893-bbs2-0004" title="RutgeertsP , SchreiberS , FeaganB , KeiningerDL , O'NeilL , FedorakRN . Certolizumab pegol, a monthly subcutaneously administered Fc‐free anti‐TNFalpha, improves health‐related quality of life in patients with moderate to severe Crohn's disease. International Journal of Colorectal Disease2008;23(3):289‐96. SchreiberS , RutgeertsP , FedorakR , Khaliq‐KareemiM , KammMA , PatelJ , et al. CDP870, a humanized anti‐TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease (CD). Gastroenterology. 2003; Vol. 124:A61. SchreiberS , RutgeertsP , FedorakRN , Khaliq‐KareemiM , KammMA , BoivinM , et al. A randomized, placebo‐controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology2005;129(3):807‐18. ">Schreiber 2005</a>). In the meta‐analysis using the Mantel‐Haenszel random‐effects method among patients with baseline CRP ≥ 10 mg/L, patients treated with CZP were significantly more likely to achieve clinical remission at week 8 than those treated with placebo: RR 1.59 (95% CI: 1.17 to 2.16). However, it was uncertain whether clinical remission at week 8 differs between CZP and placebo among patients with baseline CRP &lt; 10 mg/L in three studies involving 762 CD patients (RR 1.15, 95% CI 0.88 to 1.50) (<a href="./references#CD012893-bbs2-0002" title="NCT00152490 . A study to test the effect of CDP870 in the treatment of Crohn's disease over 26 weeks, comparing CDP870 to a dummy drug (placebo). https://clinicaltrials.gov/ct2/show/NCT00152490. SandbornWJ , FeaganBG , HoniballPJ , RutgeertsP , MasonD , BloomfieldR , et al. Certolizumab pegol for the treatment of Crohn's disease. New England Journal of Medicine2007;357(3):228‐38. SandbornWJ , FeaganBG , StoinovS , HoniballPJ , RutgeertsP , McColmJA . Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26‐week, placebo controlled phase III study (PRECiSE 1). Gastroenterology. 2006; Vol. 130:A107‐8. ">Sandborn 2007</a>; <a href="./references#CD012893-bbs2-0003" title="EUCTR‐001913‐41 . A phase IIIb, multinational, randomized, double‐blind, placebo‐controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti‐TNF‐alpha monoclonal antibody, administered subcutaneously at weeks 0, 2 and 4 in subjects with moderately to severely active Crohn’s disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=2007‐001913‐41. NCT00552058 . Study to evaluate efficacy and safety of certolizumab pegol for induction of remission in patients with Crohn's disease. https://ClinicalTrials.gov/show/NCT00552058. SandbornW , SchreiberS , FeaganB , RutgeertsP , YounesZ , BloomfieldR , et al. Induction therapy with certolizumab pegol in patients with moderate to severe Crohn's disease: a placebo‐controlled trial. American Journal of Gastroenterology. 2010; Vol. 105:S419. SandbornWJ , SchreiberS , FeaganBG , RutgeertsP , YounesZH , BloomfieldR , et al. Certolizumab pegol for active Crohn's disease: a placebo‐controlled, randomized trial. Clinical Gastroenterology &amp; Hepatology2011;9(8):670‐8. ">Sandborn 2011</a>; <a href="./references#CD012893-bbs2-0004" title="RutgeertsP , SchreiberS , FeaganB , KeiningerDL , O'NeilL , FedorakRN . Certolizumab pegol, a monthly subcutaneously administered Fc‐free anti‐TNFalpha, improves health‐related quality of life in patients with moderate to severe Crohn's disease. International Journal of Colorectal Disease2008;23(3):289‐96. SchreiberS , RutgeertsP , FedorakR , Khaliq‐KareemiM , KammMA , PatelJ , et al. CDP870, a humanized anti‐TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease (CD). Gastroenterology. 2003; Vol. 124:A61. SchreiberS , RutgeertsP , FedorakRN , Khaliq‐KareemiM , KammMA , BoivinM , et al. A randomized, placebo‐controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology2005;129(3):807‐18. ">Schreiber 2005</a>). </p> </section> <section id="CD012893-sec-0076"> <h4 class="title">Sensitivity analyses</h4> <p>We conducted three prespecified sensitivity analyses to evaluate clinical remission at week eight based on excluded studies with high risk of bias, studies using available case data instead of ITT analysis, and studies with the approved regimen of CZP. We did not conduct a sensitivity analysis of selecting later outcome assessment points because we obtained outcomes at prespecified assessment points. </p> <p>We excluded a study with high risk of bias (<a href="./references#CD012893-bbs2-0004" title="RutgeertsP , SchreiberS , FeaganB , KeiningerDL , O'NeilL , FedorakRN . Certolizumab pegol, a monthly subcutaneously administered Fc‐free anti‐TNFalpha, improves health‐related quality of life in patients with moderate to severe Crohn's disease. International Journal of Colorectal Disease2008;23(3):289‐96. SchreiberS , RutgeertsP , FedorakR , Khaliq‐KareemiM , KammMA , PatelJ , et al. CDP870, a humanized anti‐TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease (CD). Gastroenterology. 2003; Vol. 124:A61. SchreiberS , RutgeertsP , FedorakRN , Khaliq‐KareemiM , KammMA , BoivinM , et al. A randomized, placebo‐controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology2005;129(3):807‐18. ">Schreiber 2005</a>), and clinical remission at week 8 was assessed in 3 studies involving 1193 CD patients (<a href="./references#CD012893-bbs2-0001" title="NCT00291668 . Clinical study of CDP870/Certolizumab Pegol in patients with active Crohn's disease. https://clinicaltrials.gov/ct2/show/study/NCT00291668. OgataH , ItoH , MotoyaS , TakazoeM , SuzukiY , MatsumotoT , et al. Certolizumab pegol is effective at inducing and maintaining response and remission in Japanese patients with Crohn’s disease: Results from induction and maintenance studies. Gut. 2009; Vol. 58:A170. ">Ogata 2009</a>; <a href="./references#CD012893-bbs2-0002" title="NCT00152490 . A study to test the effect of CDP870 in the treatment of Crohn's disease over 26 weeks, comparing CDP870 to a dummy drug (placebo). https://clinicaltrials.gov/ct2/show/NCT00152490. SandbornWJ , FeaganBG , HoniballPJ , RutgeertsP , MasonD , BloomfieldR , et al. Certolizumab pegol for the treatment of Crohn's disease. New England Journal of Medicine2007;357(3):228‐38. SandbornWJ , FeaganBG , StoinovS , HoniballPJ , RutgeertsP , McColmJA . Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26‐week, placebo controlled phase III study (PRECiSE 1). Gastroenterology. 2006; Vol. 130:A107‐8. ">Sandborn 2007</a>; <a href="./references#CD012893-bbs2-0003" title="EUCTR‐001913‐41 . A phase IIIb, multinational, randomized, double‐blind, placebo‐controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti‐TNF‐alpha monoclonal antibody, administered subcutaneously at weeks 0, 2 and 4 in subjects with moderately to severely active Crohn’s disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=2007‐001913‐41. NCT00552058 . Study to evaluate efficacy and safety of certolizumab pegol for induction of remission in patients with Crohn's disease. https://ClinicalTrials.gov/show/NCT00552058. SandbornW , SchreiberS , FeaganB , RutgeertsP , YounesZ , BloomfieldR , et al. Induction therapy with certolizumab pegol in patients with moderate to severe Crohn's disease: a placebo‐controlled trial. American Journal of Gastroenterology. 2010; Vol. 105:S419. SandbornWJ , SchreiberS , FeaganBG , RutgeertsP , YounesZH , BloomfieldR , et al. Certolizumab pegol for active Crohn's disease: a placebo‐controlled, randomized trial. Clinical Gastroenterology &amp; Hepatology2011;9(8):670‐8. ">Sandborn 2011</a>). In the meta‐analysis using the Mantel‐Haenszel random‐effects method, patients treated with CZP were significantly more likely to achieve clinical remission at week 8 than those treated with placebo (RR 1.29, 95% CI: 1.05 to 1.59). We found no studies with unclear risk of bias in any domain of the risk of bias evaluation. </p> <p>For the available case data analysis, clinical remission at week 8 was assessed in 4 studies involving 1463 CD patients (<a href="./references#CD012893-bbs2-0001" title="NCT00291668 . Clinical study of CDP870/Certolizumab Pegol in patients with active Crohn's disease. https://clinicaltrials.gov/ct2/show/study/NCT00291668. OgataH , ItoH , MotoyaS , TakazoeM , SuzukiY , MatsumotoT , et al. Certolizumab pegol is effective at inducing and maintaining response and remission in Japanese patients with Crohn’s disease: Results from induction and maintenance studies. Gut. 2009; Vol. 58:A170. ">Ogata 2009</a>; <a href="./references#CD012893-bbs2-0002" title="NCT00152490 . A study to test the effect of CDP870 in the treatment of Crohn's disease over 26 weeks, comparing CDP870 to a dummy drug (placebo). https://clinicaltrials.gov/ct2/show/NCT00152490. SandbornWJ , FeaganBG , HoniballPJ , RutgeertsP , MasonD , BloomfieldR , et al. Certolizumab pegol for the treatment of Crohn's disease. New England Journal of Medicine2007;357(3):228‐38. SandbornWJ , FeaganBG , StoinovS , HoniballPJ , RutgeertsP , McColmJA . Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26‐week, placebo controlled phase III study (PRECiSE 1). Gastroenterology. 2006; Vol. 130:A107‐8. ">Sandborn 2007</a>; <a href="./references#CD012893-bbs2-0003" title="EUCTR‐001913‐41 . A phase IIIb, multinational, randomized, double‐blind, placebo‐controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti‐TNF‐alpha monoclonal antibody, administered subcutaneously at weeks 0, 2 and 4 in subjects with moderately to severely active Crohn’s disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=2007‐001913‐41. NCT00552058 . Study to evaluate efficacy and safety of certolizumab pegol for induction of remission in patients with Crohn's disease. https://ClinicalTrials.gov/show/NCT00552058. SandbornW , SchreiberS , FeaganB , RutgeertsP , YounesZ , BloomfieldR , et al. Induction therapy with certolizumab pegol in patients with moderate to severe Crohn's disease: a placebo‐controlled trial. American Journal of Gastroenterology. 2010; Vol. 105:S419. SandbornWJ , SchreiberS , FeaganBG , RutgeertsP , YounesZH , BloomfieldR , et al. Certolizumab pegol for active Crohn's disease: a placebo‐controlled, randomized trial. Clinical Gastroenterology &amp; Hepatology2011;9(8):670‐8. ">Sandborn 2011</a>; <a href="./references#CD012893-bbs2-0004" title="RutgeertsP , SchreiberS , FeaganB , KeiningerDL , O'NeilL , FedorakRN . Certolizumab pegol, a monthly subcutaneously administered Fc‐free anti‐TNFalpha, improves health‐related quality of life in patients with moderate to severe Crohn's disease. International Journal of Colorectal Disease2008;23(3):289‐96. SchreiberS , RutgeertsP , FedorakR , Khaliq‐KareemiM , KammMA , PatelJ , et al. CDP870, a humanized anti‐TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease (CD). Gastroenterology. 2003; Vol. 124:A61. SchreiberS , RutgeertsP , FedorakRN , Khaliq‐KareemiM , KammMA , BoivinM , et al. A randomized, placebo‐controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology2005;129(3):807‐18. ">Schreiber 2005</a>). In the meta‐analysis using the Mantel‐Haenszel random‐effects method, patients treated with CZP were significantly more likely to achieve clinical remission at week 8 than those treated with placebo (RR 1.36, 95% CI: 1.11 to 1.67). </p> <p>Clinical remission at week 8 with the approved regimen of CZP was assessed in 3 studies involving 1147 CD patients (<a href="./references#CD012893-bbs2-0001" title="NCT00291668 . Clinical study of CDP870/Certolizumab Pegol in patients with active Crohn's disease. https://clinicaltrials.gov/ct2/show/study/NCT00291668. OgataH , ItoH , MotoyaS , TakazoeM , SuzukiY , MatsumotoT , et al. Certolizumab pegol is effective at inducing and maintaining response and remission in Japanese patients with Crohn’s disease: Results from induction and maintenance studies. Gut. 2009; Vol. 58:A170. ">Ogata 2009</a>; <a href="./references#CD012893-bbs2-0002" title="NCT00152490 . A study to test the effect of CDP870 in the treatment of Crohn's disease over 26 weeks, comparing CDP870 to a dummy drug (placebo). https://clinicaltrials.gov/ct2/show/NCT00152490. SandbornWJ , FeaganBG , HoniballPJ , RutgeertsP , MasonD , BloomfieldR , et al. Certolizumab pegol for the treatment of Crohn's disease. New England Journal of Medicine2007;357(3):228‐38. SandbornWJ , FeaganBG , StoinovS , HoniballPJ , RutgeertsP , McColmJA . Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26‐week, placebo controlled phase III study (PRECiSE 1). Gastroenterology. 2006; Vol. 130:A107‐8. ">Sandborn 2007</a>; <a href="./references#CD012893-bbs2-0003" title="EUCTR‐001913‐41 . A phase IIIb, multinational, randomized, double‐blind, placebo‐controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti‐TNF‐alpha monoclonal antibody, administered subcutaneously at weeks 0, 2 and 4 in subjects with moderately to severely active Crohn’s disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=2007‐001913‐41. NCT00552058 . Study to evaluate efficacy and safety of certolizumab pegol for induction of remission in patients with Crohn's disease. https://ClinicalTrials.gov/show/NCT00552058. SandbornW , SchreiberS , FeaganB , RutgeertsP , YounesZ , BloomfieldR , et al. Induction therapy with certolizumab pegol in patients with moderate to severe Crohn's disease: a placebo‐controlled trial. American Journal of Gastroenterology. 2010; Vol. 105:S419. SandbornWJ , SchreiberS , FeaganBG , RutgeertsP , YounesZH , BloomfieldR , et al. Certolizumab pegol for active Crohn's disease: a placebo‐controlled, randomized trial. Clinical Gastroenterology &amp; Hepatology2011;9(8):670‐8. ">Sandborn 2011</a>). In the meta‐analysis using the Mantel‐Haenszel random‐effects method, patients treated with CZP were significantly more likely to achieve clinical remission at week 8 than those treated with placebo (RR 1.28, 95% CI 1.03 to 1.57). </p> </section> <section id="CD012893-sec-0077"> <h4 class="title">Funnel plots</h4> <p>We did not generate funnel plots to evaluate potential publication bias because there were less than 10 eligible trials for each pooled analysis. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012893-sec-0078" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012893-sec-0078">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012893-sec-0130">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012893-sec-0078"></div> <section id="CD012893-sec-0079"> <h3 class="title" id="CD012893-sec-0079">Summary of main results</h3> <p>We included 4 studies with 1485 patients in our meta‐analyses of the main outcomes. Patients treated with CZP were significantly more likely to achieve clinical remission (CDAI ≤150) at week 8 than those treated with placebo. The efficacy of CZP was robust in a sensitivity analysis limited to studies with a low risk of bias. Similarly, patients treated with CZP were significantly more likely to achieve clinical response (CDAI reduction ≥ 100 or clinical remission) at week 8 than those treated with placebo. These results suggest a clear benefit of CZP for active CD patients. Higher CRP improvement in patients with CZP than those with placebo is in accordance with this evidence. With respect to safety, there may be no clear difference in adverse events and withdrawal due to adverse events. Moreover, it is uncertain whether the risk of serious adverse events differs between CZP and placebo as the 95% CI includes the possibility of a small decrease or doubling of events. </p> </section> <section id="CD012893-sec-0080"> <h3 class="title" id="CD012893-sec-0080">Overall completeness and applicability of evidence</h3> <p>We included both published and unpublished data in this review. All studies were funded by the pharmaceutical company, and we contacted the company to acquire the data not reported in the published articles. To our knowledge based on our systematic literature search, this review included all the existing data to evaluate the efficacy and safety of CZP for induction of remission in CD. </p> <p>All study participants had moderate to severe CD (CDAI 220 to 450), and the evidence cannot be applied to people with mild CD (CDAI &lt; 220) and extremely severe CD (CDAI &gt; 450). Moreover, most of the patients were adults (≥ 18 years), and this review does not provide any evidence regarding pediatric CD patients. Finally, long‐term efficacy of more than 8 weeks and safety of more than 28 weeks were not evaluated in this review. A future review to evaluate maintenance of remission is warranted. </p> </section> <section id="CD012893-sec-0081"> <h3 class="title" id="CD012893-sec-0081">Quality of the evidence</h3> <p>According to the GRADE system, the overall certainty of evidence was moderate for both clinical remission and clinical response at week 8. Three out of four included studies were rated as low risk of bias for all domains (<a href="./references#CD012893-bbs2-0001" title="NCT00291668 . Clinical study of CDP870/Certolizumab Pegol in patients with active Crohn's disease. https://clinicaltrials.gov/ct2/show/study/NCT00291668. OgataH , ItoH , MotoyaS , TakazoeM , SuzukiY , MatsumotoT , et al. Certolizumab pegol is effective at inducing and maintaining response and remission in Japanese patients with Crohn’s disease: Results from induction and maintenance studies. Gut. 2009; Vol. 58:A170. ">Ogata 2009</a>; <a href="./references#CD012893-bbs2-0002" title="NCT00152490 . A study to test the effect of CDP870 in the treatment of Crohn's disease over 26 weeks, comparing CDP870 to a dummy drug (placebo). https://clinicaltrials.gov/ct2/show/NCT00152490. SandbornWJ , FeaganBG , HoniballPJ , RutgeertsP , MasonD , BloomfieldR , et al. Certolizumab pegol for the treatment of Crohn's disease. New England Journal of Medicine2007;357(3):228‐38. SandbornWJ , FeaganBG , StoinovS , HoniballPJ , RutgeertsP , McColmJA . Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26‐week, placebo controlled phase III study (PRECiSE 1). Gastroenterology. 2006; Vol. 130:A107‐8. ">Sandborn 2007</a>; <a href="./references#CD012893-bbs2-0003" title="EUCTR‐001913‐41 . A phase IIIb, multinational, randomized, double‐blind, placebo‐controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti‐TNF‐alpha monoclonal antibody, administered subcutaneously at weeks 0, 2 and 4 in subjects with moderately to severely active Crohn’s disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=2007‐001913‐41. NCT00552058 . Study to evaluate efficacy and safety of certolizumab pegol for induction of remission in patients with Crohn's disease. https://ClinicalTrials.gov/show/NCT00552058. SandbornW , SchreiberS , FeaganB , RutgeertsP , YounesZ , BloomfieldR , et al. Induction therapy with certolizumab pegol in patients with moderate to severe Crohn's disease: a placebo‐controlled trial. American Journal of Gastroenterology. 2010; Vol. 105:S419. SandbornWJ , SchreiberS , FeaganBG , RutgeertsP , YounesZH , BloomfieldR , et al. Certolizumab pegol for active Crohn's disease: a placebo‐controlled, randomized trial. Clinical Gastroenterology &amp; Hepatology2011;9(8):670‐8. ">Sandborn 2011</a>), and only <a href="./references#CD012893-bbs2-0004" title="RutgeertsP , SchreiberS , FeaganB , KeiningerDL , O'NeilL , FedorakRN . Certolizumab pegol, a monthly subcutaneously administered Fc‐free anti‐TNFalpha, improves health‐related quality of life in patients with moderate to severe Crohn's disease. International Journal of Colorectal Disease2008;23(3):289‐96. SchreiberS , RutgeertsP , FedorakR , Khaliq‐KareemiM , KammMA , PatelJ , et al. CDP870, a humanized anti‐TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease (CD). Gastroenterology. 2003; Vol. 124:A61. SchreiberS , RutgeertsP , FedorakRN , Khaliq‐KareemiM , KammMA , BoivinM , et al. A randomized, placebo‐controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology2005;129(3):807‐18. ">Schreiber 2005</a> was judged to be high risk of bias regarding both performance and detection bias. We confirmed the robust beneficial effect of CZP in the sensitivity analysis, which excluded <a href="./references#CD012893-bbs2-0004" title="RutgeertsP , SchreiberS , FeaganB , KeiningerDL , O'NeilL , FedorakRN . Certolizumab pegol, a monthly subcutaneously administered Fc‐free anti‐TNFalpha, improves health‐related quality of life in patients with moderate to severe Crohn's disease. International Journal of Colorectal Disease2008;23(3):289‐96. SchreiberS , RutgeertsP , FedorakR , Khaliq‐KareemiM , KammMA , PatelJ , et al. CDP870, a humanized anti‐TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease (CD). Gastroenterology. 2003; Vol. 124:A61. SchreiberS , RutgeertsP , FedorakRN , Khaliq‐KareemiM , KammMA , BoivinM , et al. A randomized, placebo‐controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology2005;129(3):807‐18. ">Schreiber 2005</a>. Due to the sparse data, the overall certainty of evidence was moderate for serious adverse events. We chose not to downgrade serious adverse events for high risk of bias (i.e. due to inclusion of <a href="./references#CD012893-bbs2-0004" title="RutgeertsP , SchreiberS , FeaganB , KeiningerDL , O'NeilL , FedorakRN . Certolizumab pegol, a monthly subcutaneously administered Fc‐free anti‐TNFalpha, improves health‐related quality of life in patients with moderate to severe Crohn's disease. International Journal of Colorectal Disease2008;23(3):289‐96. SchreiberS , RutgeertsP , FedorakR , Khaliq‐KareemiM , KammMA , PatelJ , et al. CDP870, a humanized anti‐TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease (CD). Gastroenterology. 2003; Vol. 124:A61. SchreiberS , RutgeertsP , FedorakRN , Khaliq‐KareemiM , KammMA , BoivinM , et al. A randomized, placebo‐controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology2005;129(3):807‐18. ">Schreiber 2005</a> study in pooled analysis). Due to the objective nature of this outcome, we did not think that the potential for unblinding of treatment assignment would have an impact on participants experiencing a life threatening adverse event. We found no other reasons to downgrade the certainty of evidence regarding clinical remission, clinical response, and serious adverse events. </p> </section> <section id="CD012893-sec-0082"> <h3 class="title" id="CD012893-sec-0082">Potential biases in the review process</h3> <p>We systematically searched all the available resources and have contacted the pharmaceutical company that manufactures CZP. Based on this systematic search, two authors independently evaluated studies for inclusion, extracted data from the included study, assessed risk of bias for each study, and conducted GRADE evaluation for main outcomes. Because data were extracted from line graphs in <a href="./references#CD012893-bbs2-0004" title="RutgeertsP , SchreiberS , FeaganB , KeiningerDL , O'NeilL , FedorakRN . Certolizumab pegol, a monthly subcutaneously administered Fc‐free anti‐TNFalpha, improves health‐related quality of life in patients with moderate to severe Crohn's disease. International Journal of Colorectal Disease2008;23(3):289‐96. SchreiberS , RutgeertsP , FedorakR , Khaliq‐KareemiM , KammMA , PatelJ , et al. CDP870, a humanized anti‐TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease (CD). Gastroenterology. 2003; Vol. 124:A61. SchreiberS , RutgeertsP , FedorakRN , Khaliq‐KareemiM , KammMA , BoivinM , et al. A randomized, placebo‐controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology2005;129(3):807‐18. ">Schreiber 2005</a> due to a lack of detailed data, there might be slight differences between these data and the actually observed data. With respect to safety, we included data between week 0 and week 12 in <a href="./references#CD012893-bbs2-0004" title="RutgeertsP , SchreiberS , FeaganB , KeiningerDL , O'NeilL , FedorakRN . Certolizumab pegol, a monthly subcutaneously administered Fc‐free anti‐TNFalpha, improves health‐related quality of life in patients with moderate to severe Crohn's disease. International Journal of Colorectal Disease2008;23(3):289‐96. SchreiberS , RutgeertsP , FedorakR , Khaliq‐KareemiM , KammMA , PatelJ , et al. CDP870, a humanized anti‐TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease (CD). Gastroenterology. 2003; Vol. 124:A61. SchreiberS , RutgeertsP , FedorakRN , Khaliq‐KareemiM , KammMA , BoivinM , et al. A randomized, placebo‐controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology2005;129(3):807‐18. ">Schreiber 2005</a> because we could not obtain the total number of adverse events and serious adverse events for the overall follow‐up period of 20 weeks. </p> </section> <section id="CD012893-sec-0083"> <h3 class="title" id="CD012893-sec-0083">Agreements and disagreements with other studies or reviews</h3> <p>The primary result of this review, the significant effect of CZP on induction of clinical remission at week 8, was not consistent with <a href="./references#CD012893-bbs2-0022" title="FordAC , SandbornWJ , KhanKJ , HanauerSB , TalleyNJ , MoayyediP . Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta‐analysis. American Journal of Gastroenterology2011;106:644‐59. ">Ford 2011</a> but was consistent with <a href="./references#CD012893-bbs2-0029" title="KawalecP , MikrutA , WisniewskaN , PilcA . Tumor necrosis factor‐alpha antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta‐analysis. Archives of Medical Science2013;9:765‐79. ">Kawalec 2013</a>. Although both systematic reviews (<a href="./references#CD012893-bbs2-0022" title="FordAC , SandbornWJ , KhanKJ , HanauerSB , TalleyNJ , MoayyediP . Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta‐analysis. American Journal of Gastroenterology2011;106:644‐59. ">Ford 2011</a>; <a href="./references#CD012893-bbs2-0029" title="KawalecP , MikrutA , WisniewskaN , PilcA . Tumor necrosis factor‐alpha antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta‐analysis. Archives of Medical Science2013;9:765‐79. ">Kawalec 2013</a>), included the same four studies (<a href="./references#CD012893-bbs2-0002" title="NCT00152490 . A study to test the effect of CDP870 in the treatment of Crohn's disease over 26 weeks, comparing CDP870 to a dummy drug (placebo). https://clinicaltrials.gov/ct2/show/NCT00152490. SandbornWJ , FeaganBG , HoniballPJ , RutgeertsP , MasonD , BloomfieldR , et al. Certolizumab pegol for the treatment of Crohn's disease. New England Journal of Medicine2007;357(3):228‐38. SandbornWJ , FeaganBG , StoinovS , HoniballPJ , RutgeertsP , McColmJA . Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26‐week, placebo controlled phase III study (PRECiSE 1). Gastroenterology. 2006; Vol. 130:A107‐8. ">Sandborn 2007</a>; <a href="./references#CD012893-bbs2-0003" title="EUCTR‐001913‐41 . A phase IIIb, multinational, randomized, double‐blind, placebo‐controlled trial to assess the efficacy and safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti‐TNF‐alpha monoclonal antibody, administered subcutaneously at weeks 0, 2 and 4 in subjects with moderately to severely active Crohn’s disease. https://www.clinicaltrialsregister.eu/ctr‐search/search?query=2007‐001913‐41. NCT00552058 . Study to evaluate efficacy and safety of certolizumab pegol for induction of remission in patients with Crohn's disease. https://ClinicalTrials.gov/show/NCT00552058. SandbornW , SchreiberS , FeaganB , RutgeertsP , YounesZ , BloomfieldR , et al. Induction therapy with certolizumab pegol in patients with moderate to severe Crohn's disease: a placebo‐controlled trial. American Journal of Gastroenterology. 2010; Vol. 105:S419. SandbornWJ , SchreiberS , FeaganBG , RutgeertsP , YounesZH , BloomfieldR , et al. Certolizumab pegol for active Crohn's disease: a placebo‐controlled, randomized trial. Clinical Gastroenterology &amp; Hepatology2011;9(8):670‐8. ">Sandborn 2011</a>; <a href="./references#CD012893-bbs2-0004" title="RutgeertsP , SchreiberS , FeaganB , KeiningerDL , O'NeilL , FedorakRN . Certolizumab pegol, a monthly subcutaneously administered Fc‐free anti‐TNFalpha, improves health‐related quality of life in patients with moderate to severe Crohn's disease. International Journal of Colorectal Disease2008;23(3):289‐96. SchreiberS , RutgeertsP , FedorakR , Khaliq‐KareemiM , KammMA , PatelJ , et al. CDP870, a humanized anti‐TNF antibody fragment, induces clinical response with remission in patients with active Crohn's disease (CD). Gastroenterology. 2003; Vol. 124:A61. SchreiberS , RutgeertsP , FedorakRN , Khaliq‐KareemiM , KammMA , BoivinM , et al. A randomized, placebo‐controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology2005;129(3):807‐18. ">Schreiber 2005</a>; <a href="./references#CD012893-bbs2-0016" title="WinterTA , WrightJ , GhoshS , JahnsenJ , InnesA , RoundP . Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate‐to‐severe Crohn's disease: an exploratory study. Alimentary Pharmacology and Therapeutics2004;20:1337‐46. ">Winter 2004</a>), the time points used to evaluate clinical remission were different. CZP was shown to be effective in <a href="./references#CD012893-bbs2-0029" title="KawalecP , MikrutA , WisniewskaN , PilcA . Tumor necrosis factor‐alpha antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta‐analysis. Archives of Medical Science2013;9:765‐79. ">Kawalec 2013</a> (at week 4), but week 4 is still in the induction dosing period (frequent administration period). It is important to be in remission when patients start the maintenance dose at week 8 (<a href="./references#CD012893-bbs2-0037" title="SchreiberS . Certolizumab pegol for the treatment of Crohn's disease. Therapeutic Advances in Gastroenterology2011;4(6):375‐89. ">Schreiber 2011</a>). <a href="./references#CD012893-bbs2-0022" title="FordAC , SandbornWJ , KhanKJ , HanauerSB , TalleyNJ , MoayyediP . Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta‐analysis. American Journal of Gastroenterology2011;106:644‐59. ">Ford 2011</a> selected more appropriate time points to assess clinical remission (at weeks 6 to 12), but the efficacy of CZP was not shown. In our review, we selected week 8 because that week is the recommended time to switch to maintenance dosing according to the approved regimen (<a href="./references#CD012893-bbs2-0037" title="SchreiberS . Certolizumab pegol for the treatment of Crohn's disease. Therapeutic Advances in Gastroenterology2011;4(6):375‐89. ">Schreiber 2011</a>). Moreover, we did not include Winter 2004 based on our protocol, because CZP in that study was administered intravenously rather than subcutaneously. More importantly, we found an unpublished study (<a href="./references#CD012893-bbs2-0001" title="NCT00291668 . Clinical study of CDP870/Certolizumab Pegol in patients with active Crohn's disease. https://clinicaltrials.gov/ct2/show/study/NCT00291668. OgataH , ItoH , MotoyaS , TakazoeM , SuzukiY , MatsumotoT , et al. Certolizumab pegol is effective at inducing and maintaining response and remission in Japanese patients with Crohn’s disease: Results from induction and maintenance studies. Gut. 2009; Vol. 58:A170. ">Ogata 2009</a>) through contact with UCB Inc and included this in our meta‐analysis (<a href="./references#CD012893-bbs2-0001" title="NCT00291668 . Clinical study of CDP870/Certolizumab Pegol in patients with active Crohn's disease. https://clinicaltrials.gov/ct2/show/study/NCT00291668. OgataH , ItoH , MotoyaS , TakazoeM , SuzukiY , MatsumotoT , et al. Certolizumab pegol is effective at inducing and maintaining response and remission in Japanese patients with Crohn’s disease: Results from induction and maintenance studies. Gut. 2009; Vol. 58:A170. ">Ogata 2009</a>). Therefore, the results of this review can be considered to be the most comprehensive review with proper assessment time points for this topic. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012893-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/urn:x-wiley:14651858:media:CD012893:CD012893-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_t/tCD012893-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012893-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/full#CD012893-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012893-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/urn:x-wiley:14651858:media:CD012893:CD012893-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_t/tCD012893-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012893-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/full#CD012893-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012893-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/urn:x-wiley:14651858:media:CD012893:CD012893-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_t/tCD012893-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012893-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/full#CD012893-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012893-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/urn:x-wiley:14651858:media:CD012893:CD012893-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_t/tCD012893-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Certolizumab pegol versus placebo, outcome: 1.1 Clinical remission at week 8." data-id="CD012893-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Certolizumab pegol versus placebo, outcome: 1.1 Clinical remission at week 8. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/full#CD012893-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012893-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/urn:x-wiley:14651858:media:CD012893:CD012893-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_t/tCD012893-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Certolizumab pegol versus placebo, outcome: 1.2 Clinical response at week 8." data-id="CD012893-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Certolizumab pegol versus placebo, outcome: 1.2 Clinical response at week 8. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/full#CD012893-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012893-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/urn:x-wiley:14651858:media:CD012893:CD012893-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_t/tCD012893-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Certolizumab pegol versus placebo, outcome: 1.6 Serious adverse events." data-id="CD012893-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Certolizumab pegol versus placebo, outcome: 1.6 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/full#CD012893-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012893-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/urn:x-wiley:14651858:media:CD012893:CD012893-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_t/tCD012893-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Certolizumab pegol versus placebo, Outcome 1 Clinical remission at week 8." data-id="CD012893-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Certolizumab pegol versus placebo, Outcome 1 Clinical remission at week 8. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/references#CD012893-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012893-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/urn:x-wiley:14651858:media:CD012893:CD012893-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_t/tCD012893-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Certolizumab pegol versus placebo, Outcome 2 Clinical response at week 8." data-id="CD012893-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Certolizumab pegol versus placebo, Outcome 2 Clinical response at week 8. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/references#CD012893-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012893-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/urn:x-wiley:14651858:media:CD012893:CD012893-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_t/tCD012893-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Certolizumab pegol versus placebo, Outcome 3 CRP at week 8 (log‐scales of geometric mean CRP ratio between baseline and week 8)." data-id="CD012893-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Certolizumab pegol versus placebo, Outcome 3 CRP at week 8 (log‐scales of geometric mean CRP ratio between baseline and week 8). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/references#CD012893-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012893-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/urn:x-wiley:14651858:media:CD012893:CD012893-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_t/tCD012893-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Certolizumab pegol versus placebo, Outcome 4 IBDQ total score at week 8 (mean change from baseline)." data-id="CD012893-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Certolizumab pegol versus placebo, Outcome 4 IBDQ total score at week 8 (mean change from baseline). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/references#CD012893-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012893-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/urn:x-wiley:14651858:media:CD012893:CD012893-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_t/tCD012893-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Certolizumab pegol versus placebo, Outcome 5 Adverse events." data-id="CD012893-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Certolizumab pegol versus placebo, Outcome 5 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/references#CD012893-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012893-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/urn:x-wiley:14651858:media:CD012893:CD012893-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_t/tCD012893-CMP-001-06.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Certolizumab pegol versus placebo, Outcome 6 Serious adverse events." data-id="CD012893-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Certolizumab pegol versus placebo, Outcome 6 Serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/references#CD012893-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012893-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/urn:x-wiley:14651858:media:CD012893:CD012893-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_t/tCD012893-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Certolizumab pegol versus placebo, Outcome 7 Withdrawals due to adverse events." data-id="CD012893-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Certolizumab pegol versus placebo, Outcome 7 Withdrawals due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/references#CD012893-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012893-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/urn:x-wiley:14651858:media:CD012893:CD012893-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_t/tCD012893-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Certolizumab pegol versus placebo, Outcome 8 Clinical remission at week 8 (Subgroup analysis based on CZP doses)." data-id="CD012893-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Certolizumab pegol versus placebo, Outcome 8 Clinical remission at week 8 (Subgroup analysis based on CZP doses). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/references#CD012893-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012893-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/urn:x-wiley:14651858:media:CD012893:CD012893-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_t/tCD012893-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Certolizumab pegol versus placebo, Outcome 9 Clinical remission at week 8 (Subgroup analysis of no previous treatment with TNF‐α inhibitors)." data-id="CD012893-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Certolizumab pegol versus placebo, Outcome 9 Clinical remission at week 8 (Subgroup analysis of no previous treatment with TNF‐α inhibitors). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/references#CD012893-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012893-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/urn:x-wiley:14651858:media:CD012893:CD012893-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_t/tCD012893-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Certolizumab pegol versus placebo, Outcome 10 Clinical remission at week 8 (Subgroup analysis of CRP levels at baseline)." data-id="CD012893-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Certolizumab pegol versus placebo, Outcome 10 Clinical remission at week 8 (Subgroup analysis of CRP levels at baseline). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/references#CD012893-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012893-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/urn:x-wiley:14651858:media:CD012893:CD012893-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_t/tCD012893-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Certolizumab pegol versus placebo, Outcome 11 Clinical remission at week 8 (Sensitivity analysis of excluding studies with high risk of bias)." data-id="CD012893-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Certolizumab pegol versus placebo, Outcome 11 Clinical remission at week 8 (Sensitivity analysis of excluding studies with high risk of bias). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/references#CD012893-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012893-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/urn:x-wiley:14651858:media:CD012893:CD012893-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_t/tCD012893-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Certolizumab pegol versus placebo, Outcome 12 Clinical remission at week 8 (sensitivity analysis of using available case data)." data-id="CD012893-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Certolizumab pegol versus placebo, Outcome 12 Clinical remission at week 8 (sensitivity analysis of using available case data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/references#CD012893-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012893-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/urn:x-wiley:14651858:media:CD012893:CD012893-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_t/tCD012893-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Certolizumab pegol versus placebo, Outcome 13 Clinical remission at week 8 (Sensitivity analysis of studies with the approval dosing regimen)." data-id="CD012893-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Certolizumab pegol versus placebo, Outcome 13 Clinical remission at week 8 (Sensitivity analysis of studies with the approval dosing regimen). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/references#CD012893-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/media/CDSR/CD012893/image_n/nCD012893-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012893-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Certolizumab pegol compared to placebo for induction of remission in Crohn's disease</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Certolizumab pegol compared to placebo for induction of remission in Crohn's disease</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> Patients with active Crohn's disease </p> <p><b>Settings:</b> Outpatient </p> <p><b>Intervention:</b> Certolizumab pegol </p> <p><b>Comparison:</b> Placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Certolizummab pegol</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical remission</b> </p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>198 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>270 per 1000</b> </p> <p>(220 to 329)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.36</b> </p> <p>(1.11 to 1.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1485<br/> (4 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>MODERATE</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Certolizumab pegol was shown to be superior to placebo regarding clinical remission at week 8 </p> <p>Clinical remission was defined as a CDAI &lt; 150</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clinical response</b> </p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>309 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>399 per 1000</b> </p> <p>(337 to 473)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.29</b> </p> <p>(1.09 to 1.53)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1485</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>MODERATE</b><sup>1</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Clinical response was defined as CDAI reduction ≥ 100 from baseline</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> <p>Follow‐up: 8 weeks</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>62 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>83 per 1000</b> </p> <p>(57 to 121)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RR 1.35</b> </p> <p>(0.93 to 1.97)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1485</p> <p>(4 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>MODERATE</b><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported serious adverse events included worsening Crohn's disease, infections, and malignancy </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk Ratio; CDAI: Crohn's disease activity index </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Downgraded one level due to high risk of bias in one study in the pooled analysis </p> <p><sup>2</sup> Downgraded one level due to imprecision (113 events) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Certolizumab pegol compared to placebo for induction of remission in Crohn's disease</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/full#CD012893-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012893-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Certolizumab pegol versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical remission at week 8 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [1.11, 1.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Clinical response at week 8 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [1.09, 1.53]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 CRP at week 8 (log‐scales of geometric mean CRP ratio between baseline and week 8) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.37 [‐0.49, ‐0.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 IBDQ total score at week 8 (mean change from baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.12 [‐1.27, 5.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.97, 1.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.93, 1.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1485</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.57, 1.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Clinical remission at week 8 (Subgroup analysis based on CZP doses) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Certolizumab pegol 100mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.48 [0.81, 7.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Certolizumab pegol 200mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.84 [0.75, 4.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Certolizumab pegol 400mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [1.06, 1.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Clinical remission at week 8 (Subgroup analysis of no previous treatment with TNF‐α inhibitors) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Clinical remission at week 8 (Subgroup analysis of CRP levels at baseline) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 CRP ≥ 10 mg/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>702</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [1.17, 2.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 CRP &lt; 10 mg/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>762</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.88, 1.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Clinical remission at week 8 (Sensitivity analysis of excluding studies with high risk of bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [1.05, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Clinical remission at week 8 (sensitivity analysis of using available case data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [1.11, 1.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Clinical remission at week 8 (Sensitivity analysis of studies with the approval dosing regimen) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.28 [1.03, 1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Certolizumab pegol versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012893.pub2/references#CD012893-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012893.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012893-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012893-note-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012893-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD012893-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD012893-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012893-note-0008">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012893\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012893\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012893\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012893\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012893\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012893\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012893\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012893\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012893\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012893\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012893\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012893\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012893\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012893\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012893\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012893\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012893\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012893\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=VXKc2U6b&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012893.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012893.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012893.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012893.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012893.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740716426379"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012893.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740716426383"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012893.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d9f3b3ae09368',t:'MTc0MDcxNjQyNi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 